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“When disturbed by disturbing thoughts – think of the opposite” 
 
Patañjalis Yogasutra II.33
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Summary of the Thesis  
 
Background The increasing level of antimicrobial resistance among clinical relevant 
bacteria, especially the increasing prevalence of extended-spectrum ȕ-lactamase 
(ESBL) producing Enterobacteriaceae, is of great concern in most parts of the world 
including Norway. During 2008-09 an outbreak caused by ESBL-producing (type 
CTX-M-15) Klebsiella pneumoniae occurred in the neonatal intensive care unit 
(NICU) at Stavanger University Hospital. This was the first reported NICU outbreak 
caused by ESBL-producing Enterobacteriaceae in Scandinavia.  
 
Objectives The objectives of this study were: (i) to describe the characteristics of the 
NICU outbreak and the K. pneumoniae outbreak strain(s), (ii) to investigate the 
duration of intestinal ESBL-carriage in the children affected by the outbreak, risk 
factors for prolonged carriage and intra-household transmission during colonization, 
and (iii) to characterize the ESBL-encoding plasmid of the outbreak strain, and 
examine the plasmid’s dynamics in relation to its K. pneumoniae host strain. 
 
Methods Several microbiological and molecular methods were employed in this 
study: culture-based ESBL-screening of environmental and patient samples, detection 
of ESBL and virulence genes by PCR, bacterial strain typing by XbaI pulsed-field gel 
electrophoresis (PFGE) and multilocus sequence typing, plasmid profiling by S1-
nuclease PFGE, PCR-based plasmid replicon typing, whole genome sequencing of 
plasmid DNA, and plasmid transfer, stability and fitness cost experiments. Kaplan-
Meier survival analysis was performed to determine carriage times of the K. 
pneumoniae strain in colonized infants. Cox-regression analysis was performed to 
identify risk factors for prolonged carriage. 
 
Results In total 58 children were affected by the NICU outbreak, caused by multidrug 
resistant CTX-M-15-producing K. pneumoniae (CTX-M-15-Kp). Of these, 56 were 
colonized by the ST17 outbreak strain (two children were colonized by an unrelated 
ST485 strain). No commonly encountered virulence factors were detected in the 
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outbreak strain. One child suffered a severe infection (sepsis) caused by CTX-M-15-
Kp, but no children died of reasons related to the outbreak. A probable index case was 
identified as one child and its mother, from which several CTX-M-15-Kp positive 
breast milk samples were obtained. The outbreak was contained by enforced infection 
control measures and strict cohorting of patients and health care workers. In a follow-
up study of colonized children and their families, CTX-M-15-Kp carriage for up to 
two years was confirmed in some of the children. Median carriage time was 12.5 
months. Risk factors for prolonged carriage were delivery by caesarean section and 
treatment with antibiotics (ampicillin and gentamicin) during the NICU stay. Intra-
household transmission of CTX-M-15-Kp was documented in 33% of the households. 
CTX-M-15 was encoded by a ~180 kb IncFIIK pKPN3-like plasmid (pKp848CTX) in 
the ST17 outbreak strain. pKp848CTX encoded multiple antibiotic, heavy metal and 
thermoresistance determinants. The plasmid could not be transferred from its K. 
pneumoniae host to Escherichia coli in vitro, consistent with in vivo observations. 
pKp848CTX was stably maintained by its host strain during intestinal colonization for 
up to two years. Segregational plasmid loss ranging from 0% to 17.5% in evolved 
populations was detected in vitro, but only negligible fitness costs associated with 
plasmid carriage were uncovered.  
 
Conclusion The NICU outbreak was caused by a CTX-M-15-producing ST17 K. 
pneumoniae strain, which spread efficiently among patients. The virulence properties 
of the outbreak strain seem to be low. Vertical mother-to-neonate transmission due to 
contaminated breast milk was the most likely the source of the outbreak. Children may 
become long-term faecal ESBL-carriers after colonization during a NICU outbreak, 
and represent a reservoir for intra-household ESBL-spread after hospital discharge. 
BlaCTX-M-15 was encoded by a pKPN3-like IncFIIK plasmid, pKp848CTX, which seems 
to be well adapted to CTX-M-15-Kp. The plasmid’s inability of self-transfer when 
hosted by this strain may have limited the extent of the outbreak and the duration of 
ESBL-colonization.  
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Preface 
 
Antimicrobial resistance (AMR) has reached the agenda of global policy 
makers. Its importance was recently emphasised by the World Health Organization in 
a comprehensive report, including data from 114 countries. It is clear that AMR is no 
longer a potential, but a current major threat to global public health and it is time to 
take action (1). In particular, the increasing prevalence of multidrug resistant (MDR) 
Gram-negative bacteria, expressing extended-spectrum ȕ-lactamases (ESBLs) and 
associated resistance mechanisms, causing hospital outbreaks and difficult-to-treat 
human infections has been of concern since the turn of the millennium. The diverse 
use and misuse of antibiotics across sectors (in humans, animals and agriculture), is 
considered the primary driver of AMR. The global spread of MDR human pathogens 
is a multifaceted challenge, and also hugely influenced by migration and tourism, the 
lack of access to clean water, open rather than closed sewage systems, high population 
densities and inadequate healthcare in many parts of the world.   
Compared to most parts of the world, we still have low, but increasing, levels of 
AMR in Norway (2). During 2008-09, an outbreak caused by ESBL-producing K. 
pneumoniae occurred in the neonatal intensive care unit (NICU) at Stavanger 
University Hospital. This was the first ESBL outbreak reported from a Norwegian 
NICU, and thus attracted much attention. Huge efforts were made by the NICU staff, 
the lab staff, the infection control team and the hospital management to control the 
outbreak. The gap of knowledge concerning different aspects of such an outbreak 
encouraged the initiation of several studies. 
This thesis is based on three sub-studies focusing on: (i) the characteristics of 
the NICU outbreak and the K. pneumoniae outbreak strain, (ii) the duration of 
intestinal ESBL-carriage in colonized children and intra-household transmission, and 
(iii) the characteristics of the ESBL-encoding plasmid and its dynamics in relation to 
its K. pneumoniae host strain.  
It is beyond the limit of this thesis to cover all aspects of the emergence of 
MDR Gram-negative bacteria. Thus, in the following introduction, I will concentrate 
on topics relevant for this study.  
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1 Introduction 
1.1 Enterobacteriaceae 
Enterobacteriaceae is a heterogeneous family of Gram-negative, non-
sporulating, facultative anaerobic rods, belonging to the Ȗ-proteobacteria. Most 
Enterobacteriaceae have type 1 pili (fimbriae), which enable bacterial adhesion to 
epithelial cells, and some species have flagella, which make them motile. Essential 
biochemical characteristics of Enterobacteriaceae include fermentation of sugars 
(different species ferment specific sugars), reduction of nitrate to nitrite, oxidase-
negativity and catalase-positivity. Enterobacteriaceae thrive well at temperatures 
between 25°C and 37°C, and inhabit a wide spectrum of environmental, animal and 
human niches, such as the mammalian intestine, water, soil and plants (3).  
The most clinically relevant Enterobacteriaceae may be divided into 
opportunistic pathogens, such as Citrobacter spp., Enterobacter spp. and Klebsiella 
spp., and overt pathogens, such as Shigella spp., Salmonella spp. and Yersinia spp. (4). 
E. coli may be divided into commensal strains and pathogenic strains. K. pneumoniae 
and E. coli are the most frequently observed Enterobacteriaceae in human clinical 
samples, and may cause common infections such as pneumonia, urinary tract 
infections (UTIs) and bloodstream infections (BSIs) (3, 5). 
 
1.2 Klebsiella pneumoniae 
K. pneumoniae belong to the genus Klebsiella. According to Ørskov’s 
classification, K. pneumoniae may be divided into three subspecies: K. pneumoniae 
subsp. pneumoniae, ozaenae and rhinoscleromatis (6). In this thesis, K. pneumoniae 
subsp. pneumoniae is meant when K. pneumoniae is written. 
The genus Klebsiella is named after the German-Swiss pathologist Edwin 
Klebs, who was the first to observe bacteria in the airways of patients who died of 
pneumonia in 1875. In 1882 the German pathologist and microbiologist Carl 
Friedländer detected bacteria in the fibrous exudate of patients who had died of lobar 
pneumonia, and it soon became apparent that two bacterial species could cause 
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pneumonia, Streptococcus pneumoniae and K. pneumoniae, the latter also referred to 
as Friedländers bacillus (7). 
 
1.2.1 Biochemical characteristics 
Biochemical characteristics used for the identification of K. pneumoniae 
include: negative indole-test, production of lysine decarboxylase (but not ornithine 
decarboxylase), fermentation of specific sugars (e.g. D-glucose, lactose, sucrose, L-
arabinose and maltose) and sugar-alcohols (e.g. D-mannitol). Furthermore, K. 
penumoniae is non-motile and usually produce a prominent acidic polysaccharide-
based capsule (8). Biochemical characteristics are still being used for species 
identification of bacteria isolated from clinical samples. However, biochemical 
identification is increasingly performed by automated systems, such as Vitek2 
(bioMèrieux, Marcy l’Etoile, France) or Phoenix (BD Diagnostics, Sparks, USA). 
Moreover, new identification approaches, such as MALDI-TOF mass spectrometry, 
has been taken into use in many laboratories with great success.  
 
1.2.2 Pathogenicity and virulence factors 
The pathogenicity of Klebsiella spp. may be associated with virulence factors, 
such as capsular antigens (O- and K-antigens), adhesins, siderophores and 
lipopolysaccharides (endotoxins). The capsule is considered essential to the virulence 
of Klebsiella, as it protects the bacterium from phagocytosis and prevents killing of the 
bacteria by bactericidal serum factors (6).  
Some serotypes or capsular types (K-types) of K. pneumoniae, e.g. K1, K2, K5, 
K54 and K57, have been associated with invasive human infectious diseases. K1 was 
observed among isolates causing Friedländer’s pneumonia, and has more recently been 
associated with pyogenic liver abscesses (9, 10). Brisse et al. studied the association 
between K-type, sequence type (ST) and virulence gene content. The authors 
concluded that K-types are not associated with specific K. pneumoniae clones, and that 
K-types are distributed among unrelated clones by horizontal transfer of the cps 
operon, which encodes the synthesis of capsular polysaccharides. Furthermore, the 
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virulence gene content was found to be associated with specific clones, rather than 
with K-types (11). 
During recent years, several genes encoding virulence factors in K. pneumoniae 
have been described: the plasmid-borne rmpA regulates the mucoid phenotype (12), 
wcaG is associated with enhanced bacterial escape from phagocytosis (13), kfu is 
involved in iron acquisition,  fimH encodes type 1 fimbriae, mrkD encodes type 3 
fimbriae and cf29A encodes the non-fimbrial adhesion factor CF29K (11). K. 
penumoniae ST23, which is frequently of serotype K1, is considered to be a particular 
virulent clone. Presence of allS is a marker for ST23 (14). Calhau et al. recently 
detected several virulence genes and pathogenicity islands (PAIs) in a collection of 
clinical ESBL-producing K. pneumoniae isolates from renal transplant patients (15). In 
a recent Danish study, the virulence factors aerobactin, kfu and rmpA were detected in 
a hypermucoviscous K. pneumoniae ST23 blood isolate from a patient with a liver 
abscess (9). 
Klebsiella spp. are known to be inherent or intrinsically resistant to ampicillin, 
ticarcillin and piperacillin due to chromosomal SHV-1-production. Furthermore, all 
Enterobacteriaceae are intrinsically resistant to penicillin G, glycopeptides, fusidic 
acid, macrolides (with some exceptions), lincosamides, streptogramins, daptomycin 
and linezolid (16). Acquired resistance to other relevant antibiotic groups is 
increasingly reported in clinical K. pneumoniae isolates, and will be described more in 
detail further below.  
Biocides, including pesticides, preservatives for food, desinfectants and 
antiseptics, have been extensively used in agriculture, in food industry and in hospitals 
for decades. Bacterial tolerance to biocides has been observed, and concern has been 
raised on their impact on the selection of antimicrobial resistance (AMR) in human 
pathogens (17). Efflux pumps extruding both multiple biocides and antibiotics have 
been described in Enterobacteriaceae and other Gram-negative bacteria (18). Reduced 
susceptibility to the antiseptics chlorhexidine, trigene and benzalkonium chloride was 
recently documented in clinical K. pneumoniae isolates. The biocide resistance genes 
cepA and qac¨E (encoding efflux pumps) were detected in most of the isolates. There 
was, however, no genetic linkage between determinants encoding reduced biocide 
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susceptibility and antibiotic resistance (19). Furthermore, bacterial resistance to heavy 
metals, such as copper and silver, also frequently used as antiseptics, has been reported 
in clinical MDR K. pneumoniae strains (20, 21).  
Altogether, the combination of antibiotic, biocide and heavy metal resistance in 
nosocomial pathogens, such as K. pneumoniae, may favour their selection and 
dissemination in the hospital environment. 
 
1.2.3 Colonization in human and dissemination in hospitals 
In humans, K. pneumoniae may colonize the skin, the naso- and oropharynx and 
the intestinal tract (22-24). Carriage rates of K. pneumoniae are generally low in 
healthy humans, but have been found to increase dramatically in hospitalized patients, 
especially in patients treated with broad-spectrum antibiotics (25-27). The healthy 
human skin is not a common reservoir for Gram-negative bacteria, but K. pneumoniae 
has been found to colonize the hands of hospitalized patients and health care workers 
(HCWs) for several hours (28, 29). K. pneumoniae may spread remarkably well in the 
hospital environment, and frequently cause nosocomial infections and outbreaks, 
especially in intensive care units (ICUs). Medical equipment, the gastrointestinal tract 
of patients and the hands of HCWs are considered the most important reservoirs for 
the spread of K. pneumoniae in the hospital environment (28, 30).  
 
1.2.4 K. pneumoniae infections  
Historically, K. pneumoniae was known as the cause of community-acquired 
pneumonia or Friedländer’s pneumonia, which particularly occurred in 
immunocompromised persons, such as chronic alcoholics. Friedländer’s pneumonia 
was a severe infection with high mortality if untreated (6). This disease has become 
rare in most parts of the world. Today, K. pneumoniae is primarily known as a 
nosocomial pathogen, but may also be associated with community-acquired 
pneumonia or UTI, especially in elderly or immunocompromised persons. More lately, 
community-acquired liver abscesses with metastatic spread caused by highly virulent 
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K. pneumoniae strains (often of serotype K1 and ST23) are increasingly observed in 
healthy subjects, especially in South East Asia (31).  
Immunocompromised hospitalized patients have an increased risk of 
opportunistic K. pneumoniae associated infections (6). Furthermore, the rate of 
nosocomial Klebsiella infections has been found to be four times higher in patients 
who carry the bacteria in their intestine than in non-carriers (32).  
K. pneumoniae belong to the top three or four pathogens causing NICU 
infections (33). A combination of factors may explain why K. pneumoniae infection is 
so common in the NICU setting. Neonates, in particular premature neonates, have an 
immature immune system and lack a protective normal flora (33, 34). Invasive 
procedures and ventilator support allow bacteria from the NICU environment to access 
the bloodstream and lungs (33). Antibiotic treatment interferes with the development 
of the neonatal intestinal flora, and especially ampicillin has been associated with 
increased Klebsiella carriage rates in neonates hospitalized in NICUs (35).  
Lower UTIs caused by K. pneumoniae may be successfully treated with per oral 
agents such as nitrofurantoin, trimethoprim and pivmecillinam. Agents available for 
treatment of upper UTIs and systemic K. pneumoniae infections include broad-
spectrum penicillins in combination with ȕ-lactamase inhibitors (e.g. piperacillin-
tazobactam), fluoroquinolones, trimethoprim-sulfamethoxazole, aminoglycocides, 
broad-spectrum cephalosporins and carbapenems. However, resistance is emerging to 
most of these antibiotics, and the treatment options of K. pneumoniae associated 
infections are becoming more and more limited. 
 
1.3 Antibacterial agents 
The antibacterial effect of penicillin was discovered by Alexander Fleming in 
1928. Since the first antibacterial agents were taken into clinical use during the late 
1930s and 40s, antibacterial chemotherapy has played a crucial role in the treatment of 
infectious diseases. Today’s specialised modern medicine, like intensive care, cancer 
therapy and advanced surgery, rely on potent antibacterial agents.  
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Figure 1. Historical timeline for the introduction of new antbiotic classes (white boxes) and new 
groups of ȕ-lactams (blue boxes).  
 
 
In the 1940s to 1960s, several antibiotic classes with different modes of action 
were detected and developed for clinical use (Figure 1). However, after the 
introduction of trimethoprim in 1968, no new classes of antibiotics effective in the 
treatment of Gram-negative bacterial infections have been discovered. The 3rd 
generation cephalosporins and a unique class of ȕ-lactams, the carbapenems, were 
introduced in the 1980s. Furthermore, a large number of broad-spectrum 
cephalosporins and quinolones was introduced in the years to come, but these were all 
chemical modifications of agents already in clinical use (36). The lack of new drugs 
effective in the treatment of Gram-negative bacterial infections along with the 
emergence of antibacterial resistance Gram-negative pathogens has become a serious 
threat for modern medicine.  
Antibacterial agents differ in their mode of action, antimicrobial spectra, 
pharmacologic parameters (i.e. pharmacokinetics and -dynamics) and toxicity. 
Antibacterial agents are frequently classified into five groups according to their mode 
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of action and antibacterial target: (i) inhibitors of the cell wall synthesis (e.g. ȕ-
lactams, glycopeptides), (ii) inhibitors of the DNA/RNA synthesis (e.g. quinolones, 
nitroimidazoles, rifampicin), (iii) inhibitors of the folic acid synthesis (e.g. 
sulphonamides, trimethoprim), (iv) inhibitors of the protein synthesis (e.g. 
aminoglycocides, macrolides, tetracyclines) and (v) inhibitors of the cytoplasmic 
membrane (e.g. polymyxins) (37). 
 
1.3.1 ȕ-lactams  
Due to their diversity, broad spectrum of activity and low toxicity, ȕ-lactams 
are the most prescribed antibiotics worldwide (38). All ȕ-lactams have the ȕ-lactam 
ring in common. Due to differences in their side chains, ȕ-lactams may be classified 
into the following main groups: penicillins, cephalosporins, monobactams and 
carbapenems (Table 1) (37). ȕ-lactams target the bacterial cell wall synthesis and act 
by binding covalently to penicillin binding proteins (PBPs). PBPs are bacterial 
enzymes involved in the synthesis and crosslinking of peptidoglycan, which is a major 
component of the bacterial cell wall. PBPs are located in the inner cytoplasmic 
membrane or in the periplasmatic space of Gram-negative bacteria. When PBPs are 
inactivated by ȕ-lactams, the peptidoglycan synthesis is inhibited and the bacterial 
growth is affected. Irregularities in the cell wall synthesis lead to loss of integrity and 
finally cell lysis (39).  
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Table 1. Main goups and sub-classes of ȕ-lactam antibiotics in clinical use in Norway (2014). 
Group Sub-classes Agents
Penicillins
Benzylpenicillin 
Narrow-spectrum 
penicillins 
Benzylpenicillin, 
benzathinepenicillin, 
phenoxymethylpenicillin 
  
ȕ-lactamase-stable 
penicillins 
Cloxacillin, dicloxacillin 
  
Broad-spectrum 
penicillins 
Amoxicillin, ampicillin, mecillinam, 
pivmecillinam 
  
Broad-spectrum 
penicillin +  
ȕ-lactamase-inhibitor  
Piperacillin-tazobactam 
   
Cephalosporins
Cefotaxime 
1st generation Cephalexin, cephalothin 
  
2nd generation Cefuroxime 
  
3rd generation Cefotaxime, ceftazidime, ceftriaxone 
  
4th generation Cefixim (treatment of gonorrhoeae)
  
5th generation Ceftaroline (treatment of MRSA or 
PNSP associated infections) 
   
Monobactams Aztreonam 
   
Carbapenems Imipenem, doripenem, ertapenem, 
meropenem 
1.4 Resistance to antibacterial agents 
Since antibacterial agents were taken into clinical use, resistance to most classes 
of relevant antibiotics, including the ȕ-lactams, has emerged among human pathogens. 
Sir Alexander Fleming warned in his Nobel lecture in 1945 that resistance may evolve 
if antibacterial drugs are misused or under-dosed: “It is not difficult to make microbes 
resistant to penicillin in the laboratory by exposing them to concentrations not 
sufficient to kill them, and the same thing occasionally happened in the body” 
(Alexander Fleming, Nobel lecture “Penicillin”, 1945).  
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1.4.1 Definitions 
• Minimum inhibitory concentration: The minimum inhibitory concentration 
(MIC) is the lowest antimicrobial concentration that inhibits visible growth of 
microorganism after overnight (ON) incubation in vitro (40). MICs are used in 
microbiological laboratories to measure the activity of an antimicrobial agent 
against a specific microorganism.  
• Clinical susceptibility and resistance: Since the 1970s, clinical breakpoints 
(based on MIC values) have been determined and used in microbiology 
laboratories to categorize microorganisms as susceptible (S), intermediate (I), 
or resistant (R). The S/I/R categorization provides guidance to clinicians with 
respect to the potential success of a given agent in the treatment of an infection, 
caused by a specific organism. S, I and R has been defined by the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) (41). 
• Microbiological resistance: A microorganism is defined as wild type for a 
species by the absence of acquired resistance mechanisms to the drug in 
question. The epidemiological cut-off value (ECOFF) is a MIC value, which 
identifies the upper limit of measured MIC values for a given wild type 
population. ECOFFs are considered when setting clinical breakpoints, and they 
are useful indicators of developing resistance in surveillance studies. There is 
no systematic relationship between clinical breakpoints and ECOFFs (41).  
• Setting clinical breakpoints: From a clinical point of view, AMR is a relative 
phenomenon influenced by the following factors, which must be considered 
when setting clinical breakpoints: available formulations of the agent (e.g. oral 
or intravenous), standard and maximum dosing, clinical indications, target 
organism, MIC distributions and ECOFFs for individual species (wild-type), 
pharmacokinetic (PK) and pharmacodynamic (PD) data, clinical data relating 
outcome to MIC values, information on resistance mechanisms and the clinical 
significance of the resistance mechanisms. Of notice, clinical breakpoints for 
susceptibility testing should not divide wild-type distributions of the target 
species (42). 
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• Antimicrobial susceptibility testing: Antimicrobial susceptibility testing 
(AST) may be performed in several ways. The most common method used for 
AST in routine laboratories is conventional disk diffusion, which categorize 
microorganisms as S, I or R. The use of plastic strips, containing an 
antimicrobial concentration gradient (gradient test), is a convenient way to 
generate MIC data on agar plates. Broth dilution is considered the gold standard 
of MIC determination, but is not commonly used in routine laboratories (43). 
Recently, a standardized disk diffusion method (The EUCAST method) was 
validated and implemented in several European countries, including Norway 
(44, 45). Furthermore, automated AST systems (e.g. Vitek2 and Phoenix) are 
commonly used for AST in routine laboratories, and offer the convenience of 
combining species identification and MIC determination for relevant agents. 
 
1.4.2 Mechanisms of resistance 
Antibacterial resistance may be intrinsic (natural) or acquired. Intrinsic bacterial 
resistance to antibacterials, produced by other bacteria or fungi, existed in the 
environment before antibacterial compounds were taken into clinical use. Bacteria, 
furthermore, have the remarkable ability of environmental adaptation by changing 
their genome through mutations or by horizontal gene transfer (HGT), or by 
differential gene expression (46, 47). The extensive use of antibiotics in humans, but 
also in food animals and fish farming, has led to a selective pressure in several 
environmental niches promoting acquisition of resistance determinants.  
Resistance may be acquired in three ways: (i) mutations in chromosomal genes, 
causing altered antibacterial targets or transcriptional changes, e.g. mutation in 
chromosomal topoisomerase/gyrase genes leading to fluoroquinolone resistance (48), 
(ii) acquisition of new genes by horizontal gene transfer (HGT) , e.g. plasmid-
mediated acquisition of ȕ-lactamase encoding genes (49), or (iii) mutations in 
previously acquired genes, e.g. mutation in the ȕ-lactamase genes blaTEM-1 and blaSHV-
1, resulting in production of enzymes with a broader spectrum (50). 
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Four biochemical mechanisms of antibacterial resistance have been described 
(51): (i) inactivation or modification of antibiotics by antibiotic-modifying enzymes, 
e.g. ȕ-lactamases (50) and aminoglycoside modifying enzymes (52), (ii) modification 
of the target molecule, e.g. modifications of PBPs in S.  pneumoniae (53) and 
Enterococcus faecium (54), (iii) restricted access to the target of an antibiotic due to 
reduction of porins in the outer membrane of Gram-negative bacteria, and (iv) efflux 
of one or more antibiotic groups from the bacterial cell due to efflux pumps in the 
cytoplasmic membrane. Bacteria may combine two or more of these mechanisms. 
Furthermore, in E. faecium a bypass mechanism has been described to cause 
glycopeptide resistance (55). 
 
1.4.3 Mechanisms of ȕ-lactam resistance 
Resistance to ȕ-lactams may be PBP-mediated, or caused by production of ȕ-
lactamases. Porin loss or down-regulation may cause ȕ-lactam resistance alone, or in 
combination with ȕ-lactamase production. In Pseudomonas aeruginosa  down-
regulation of the porin OMPD2 in combination with production of chromosomal 
AmpC ȕ-lactamase may result in an imipenem resistant phenotype (56). PBP-mediated 
resistance may be caused by acquisition of foreign PBPs, e.g. acquisition of the gene 
encoding PBP2a in methicillin resistant S. aureus (MRSA) (57), or by modifications 
of PBPs, e.g. penicillin non-susceptible S. pneumoniae (PNSP) due to mosaic PBPs 
(58).  
ȕ-lactamase production is the most common mechanism of ȕ-lactam resistance 
in Gram-negative bacteria. ȕ-lactamases are enzymes, which may inactivate ȕ-lactam 
antibiotics by hydrolysing the amide bond of the ȕ-lactam ring (59). ȕ-lactamases may 
be classified based on their primary structure according to Ambler (60), or due to their 
functional characteristics (i.e. the enzymes abilities to hydrolyse different ȕ-lactam 
classes) according to Bush-Jacoby-Medeiros (61-64). The serine ȕ-lactamases (Ambler 
class A) share several highly conserved amino acid sequences with PBPs, from which 
they probably evolved (65, 66). As for the ȕ-lactam antibiotics, also the ȕ-lactamases 
vary in their spectrum of activity depending on the structure of their side chains, and 
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they may be subdivided into: (i) narrow-spectrum ȕ-lactamases (penicillinases), (ii) 
broad-spectrum ȕ-lactamases (ampicillinases), (iii) extended-spectrum ȕ-lactamases 
(ESBLs), which may hydrolyse 3rd and 4th generation cephalosporins and 
monobactams, and (iv) carbapenemases, which may hydrolyse all ȕ-lactams, including 
the carbapenems. 
 
1.5 ȕ-lactams and ȕ-lactamases in a historical perspective 
As penicillin was taken into clinical use during the early 1940s, it was 
considered the “magic bullet” against all Gram-positive bacteria (65). Infections 
caused by S. aureus, Streptococcus pyogenes and S. pneumoniae could effectively be 
cured. However, the understanding of antibiotic prescription and infection control was 
rudimentary, and little awareness of AMR existed.  
The first ȕ-lactamase (i.e. penicillinase) in clinical isolates of S. aureus was 
observed only a few years after the introduction of penicillin (67). Soon, a pandemic of 
hospital-associated staphylococcal infections due to penicillinase producing clones 
emerged worldwide (65). In the early 1960s, the penicillinase stabile methicillin was 
introduced to combat staphylococcal infections, and more attention was paid to 
infection control and prudent use of antibiotic. During the next two decades, several 
new ȕ-lactams with a broader antimicrobial spectrum were released and widely used. 
Ampicillin was the first penicillin with activity against Gram-negative bacteria. In 
1963, the first clinical E. coli isolate producing an R-factor or plasmid-mediated 
broad-spectrum ȕ-lactamase (i.e. ampicillinase) was isolated in Athens from a patient 
called Temoneira, and thus named TEM-1 after this patient (68). Soon after, a second 
plasmid-mediated ampicillinase, SHV-1, was detected among K. pneumoniae and 
other Enterobacteriaceae. Both TEM-1 and SHV-1 encoding genes, carried by 
conjugative transposons and plasmids, spread rapidly and became ubiquitous in Gram-
negative bacteria (69) and TEM-1-producing K. pneumoniae became endemic in many 
hospitals (65).  
During the 1980-90s, several ȕ-lactams with extended-spectrum were 
introduced. A new era of antibacterial therapy had begun. However, as environmental, 
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commensal and pathogenic bacteria were exposed to the new agents, novel ȕ-
lactamases with extended-spectrum rapidly emerged among clinical isolates.  
Already in 1979, induction of the chromosomal AmpC ȕ-lactamase of Enterobacter 
cloacae was recognized (70, 71).  In 1983, the first K. pneumoniae isolate resistant to 
3rd generation cephalosporins was discovered in Germany (72). The new ȕ-lactamase, 
which conferred resistance to cefotaxime, was a mutation-driven alteration of the 
existing SHV-1 enzyme, and thus designated SHV-2 (73). The first TEM-derived ȕ-
lactamase conferring resistance to cefotaxime, TEM-3 (initially named CTX-1), was 
reported in K. pneumoniae from France a few years later (74, 75). In 1988, the term 
extended-spectrum ȕ-lactamase (ESBL) was introduced (76). Due to widespread use 
of broad-spectrum cephalosporins, such as ceftazidime and cefotaxime, numerous 
TEM- and SHV-mutants with extended spectrum evolved. During the early 1990s, 
ESBL-producing K. pneumoniae emerged as a nosocomial pathogen, causing hospital-
acquired infections and hospital outbreaks (77, 78). In 1989, a clinical cefotaxime 
resistant E. coli isolate, producing a non-TEM/SHV ESBL, was recognized in Munich. 
The new enzyme was designated CTX-M due to its predominant activity against 
cefotaxime rather than ceftazidime, and the geographical reference (79). A shift from 
the predominance of TEM- and SHV-enzymes among K. pneumoniae in the hospital 
setting to the dissemination of CTX-M-enzymes among E. coli and K. pneumoniae, 
also in the community, was observed (80-82).  
The first plasmid-mediated AmpC ȕ-lactamases were reported in K. 
pneumoniae in 1990 (83). In 1991, the first oxacillinases (OXA-10-group) conferring 
resistance to 3rd generation cephalosporins were detected in Turkey (84). Since 1990, 
several new ESBL-groups conferring resistance to the carbapenems have been 
detected in clinical isolates all over the world. Imipenem resistance in P. aeruginosa 
due to a plasmid-mediated metallo-ȕ-lactamase (MBL) was reported from Japan in 
1991 (85). The first carbapenem hydrolysing OXA-enzyme (OXA-23) was described 
in Acinetobacter baumanii in 1993 (86). OXA-48 was identified in a Turkish 
carbapenem resistant K. pneumoniae isolate in 2001 (87). The first K. pneumoniae 
carbapenemase (KPC-1) was reported from USA in 2001 (88). In 2009, a carbapenem 
resistant K. pneumoniae isolate, producing a novel MBL, designated New-Delhi 
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metallo-ȕ-lactamase-1 (NDM-1), was isolated from a Swedish patient (89). NDM-1 
has the potential to spread rapidly among clinically relevant Enterobacteriacea (90). 
Thus, the detection of this enzyme attracted much attention and publicity. The current 
spread of the carbapenamases KPC, VIM, IMP and NDM among Enterobacteriaceae 
cause great concern (91). 
 
1.6 Extended-spectrum ȕ-lactamases (ESBLs) 
1.6.1 ESBL-classifications and definitions 
ESBLs may, like other ȕ-lactamases, be classified based on their primary 
structure according to Ambler (60), and their functional characteristics according to 
Bush-Jacoby (64). Due to these classification systems, a “classical ESBL” is a 
molecular class A and a functional class 2be enzyme, which hydrolyses extended-
spectrum cephalosporins and monobactams, and is inhibited by clavulanic acid. These 
classification systems were convenient as long as the TEM- and SHV-derived ESBLs 
were dominating. However, due to the emergence of several new enzyme groups or 
families, including about 400 TEM- and SHV-ESBLs, 150 CTX-M- variants (92), the 
plasmid-borne AmpCs and the diverse spectrum of carbapenamases, the scientific 
nomenclature has become too complex for daily clinical use. Also the ESBL-definition 
has been debated (93). In 2009, Giske et al. proposed to include plasmid-mediated 
AmpC, OXA-enzymes and carbapenamases in the ESBL-definition, and a simplified 
ESBL-classification was introduced (94). ESBLs were proposed classified in to three 
main categories: ESBLA, ESBLM, and ESBLCARBA. The “classical ESBLs” were 
designated ESBLA in the novel classification. ESBLM was subdivided into MSBLM-C 
and ESBLM-D, whereas ESBLCARBA was subdivided into ESBLCARBA-A, ESBLCARBA-B 
and ESBLCARBA-D (Table 2). In contrast to former definitions, the novel ESBL-
definition includes all acquired ȕ-lactamases with hydrolytic activity against extended-
spectrum cephalosporins and/or carbapenems. The ESBL-definition and -
classification, proposed by Giske et al., will mainly be applied in this thesis. 
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Table 2. The Extended-Spectrum ȕ-Lactamase (ESBL) classification scheme of Giske et al. (modified 
from reference 94).
ESBL-classes Examples Definitions Amblera Bush-
Jacobyb 
ESBLA “Class A 
ESBLs” 
CTX-M, 
TEM- and  
SHV-ESBLs 
Non-susceptibility to 
extended-spectrum 
cephalosporins and 
monobactams 
Inhibited by clavulanic 
acid 
Class A Group 
2be 
      
ESBLM “Miscellaneous 
ESBLs” 
Non-susceptibility to 
extended-spectrum 
cephalosporins 
      
   ESBLM-C Plasmid-
mediated AmpC 
CMY and 
DHA 
Inhibited by 
cloxacillin and boronic 
acid 
Class C Group 1 
      
   ESBLM-D OXA-ESBLs OXA-10-
group 
Inhibitor not known Class A Group 
2de 
      
ESBLCARBA “ESBLs with 
hydrolytic 
activity against 
carbapenems” 
Non-susceptibility to 
extended-spectrum 
cephalosporins and at 
least one carbapenem 
      
  ESBLCARBA-A KPC and other 
class A 
carbapenemases 
KPC and 
GES 
Inhibited by boronic 
and dipicolinic acid 
Class A Group 
2f 
      
  ESBLCARBA-B MBLs IMP, VIM 
and NDM 
Inhibited by EDTA 
and dipicolinic acid 
Class B Group 
3a 
      
   ESBLCARBA-D OXA-
carbapenamases 
OXA-23 and 
OXA-48 
Inhibitor not known Class D Group 
2df 
aFrom reference 60. bFrom reference 64. 
1.6.2 ESBL-detection 
ESBLA-producing strains may exhibit reduced susceptibility to all 
cephalosporins and monobactams. However, the substrate profile differs among 
enzyme groups (e.g. in contrast to the SHV-ESBLs, CTX-M group 9 enzymes confer 
resistance to cefotaxime, but not to ceftazidime). Phenotypical tests, including the 
inhibitor clavulanic acid, are mainly used for the detection of ESBLA (95-97). During 
recent years also more rapid methods, such as the ESBL NDP test, have become 
available for ESBL-detection (98). For epidemiological purposes, molecular detection 
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may be added to determine the ESBLA-type (99-101). CTX-M, TEM and SHV are the 
ESBLA-enzymes most frequently detected, but other ESBLA-types have also been 
described (102). 
ESBLM-C-producing strains exhibit reduced susceptibility to 1st and 2nd 
generation cephalosporins and cephamycins (cefoxitin and cefotetan), and 
intermediate susceptibility or resistance to 3rd generation cephalosporins and 
monobactams. In contrast to ESBLA, ESBLM-C-enzymes do not confer resistance to 4th 
generation cephalosporins (e.g. cefepime and cefpirome). ESBLM-C may be detected by 
phenotypic tests including cloxacillin or boronic acid (97, 103). Molecular methods 
are needed for epidemiological purposes, but also to differentiate plasmid-mediated 
ESBLM-C-production from chromosomal AmpC-hyperproduction in E.coli (104, 105). 
Furthermore, derepressed chromosomal AmpC-production in some 
Enterobacteriaceae, such as Citrobacter freundii and Enterobacter spp., may cause 
reduced susceptibility to 3rd generation cephalosporins and should also be 
discriminated from ESBLM-C (97). ESBLM-D can only be detected by molecular 
methods. 
ESBLCARBA-A-enzymes may confer reduced susceptibility to all ȕ-lactam 
antibiotics. ESBLCARBA-B-producing bacteria may be non-susceptible to all ȕ-lactam 
antibiotics, except monobactams. OXA-48, the most common ESBLCARBA-D-enzyme in 
Enterobacteriaceae (106), causes reduced susceptibility to carbapenems, but does not 
confer resistance to 3rd and 4th generation cephalosporins, and may thus be difficult to 
detect. ESBLCARBA-A and ESBLCARBA-B-enzymes may be detected phenotypically by 
using the appropriate ȕ-lactam/ȕ-lactam-inhibitor combination. So far, there is no 
known inhibitor against ESBLCARBA-D enzymes, and their presence need to be 
confirmed by molecular tests. Of notice, OXA-48-producing strains are normally 
highly resistant to temocillin, which may be used as a diagnostic marker for this 
enzyme (107). Detection and discrimination of ESBLCARBA-variants may be 
challenging. Thus, several phenotypic and molecular tests are available (97, 100, 108, 
109). More recently, detection of carbapenamase production using MALDI-TOF MS 
has been proposed (110, 111). 
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ESBLA and ESBLM-producing isolates are normally susceptible to 
carbapenems. However, the combination of ESBLA or ESBLM-production and porin 
loss, or increased efflux, may result in a carbapenem non-susceptible phenotype (112), 
which should be discriminated from true ESBLCARBA. 
ESBLs, as defined by Giske et al., are encoded by acquired genetic elements, 
which frequently carry several resistance determinants, causing co-resistance to other 
important antibiotic groups in most ESBL-producing isolates. Thus, rapid ESBL-
detection and communication of results both to clinicians and infection control staff is 
of great importance. Further information concerning both phenotypic and molecular 
detection of ESBLs and other relevant resistance mechanisms is available at the 
EUCAST website (113).  
 
1.7 Spread of ESBLs 
Antibiotic resistance genes may be located within the chromosome of a 
bacterium, or on mobile genetic elements (MGEs). Chromosomally located antibiotic 
resistance genes are mainly dispersed vertically to daughter cells through regular cell 
division (i.e. clonal spread). Resistance genes carried by MGEs may also be passed on 
horizontally (i.e. horizontal gene transfer) to more or less related bacteria (114). 
ESBL-encoding genes are mostly carried by conjugative plasmids or transposons, and 
thus efficiently disseminated both by vertical and horizontal modes (115). 
 
1.7.1 Clonal spread 
Some bacterial clones are referred to as “successful clones” due to favourable 
phenotypic traits (e.g. virulence or antibiotic resistance), which enable them to 
disseminate and persist in different environments, and cause human infections and 
outbreaks. Successful clones carrying antibiotic resistance determinants play a major 
role in the spread of resistance (116). Two examples are E. coli ST131 and K. 
pneumoniae ST258, which have contributed significantly to the worldwide spread of 
CTX-M-15 and KPC, respectively (117). 
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1.7.2 Horizontal gene transfer (HGT) 
The transfer of foreign genes between organisms is referred to as horizontal 
gene transfer (HGT) (114). HGT most commonly take place between closely related 
organisms, but may also take place between different species, genera and kingdoms 
(for example between bacteria and plants). The association of HGT to the spread of 
antibiotic resistance among bacteria was recognized by Japanese investigators already 
in the late 1950s (118). There are three mechanisms of HGT: (i) transformation is the 
active uptake of free DNA from the environment by competent bacterial cells, (ii) 
transduction is an infection of bacteria by bacteriophages or bacterial viruses, who 
inject foreign DNA into a bacterial cell, and (iii) conjugation is the mechanism where 
a donor and a recipient cell physically connect to each other and share DNA carried by 
conjugative elements, such as plasmids and transposons (114). Foreign DNA captured 
by transformation, transduction or conjugation may be integrated into the bacterial 
chromosome, whereas plasmids normally exist as independent genetic entities in a 
bacterial cell (114).  
 
1.7.3 Mobile genetic elements (MGEs) 
The mobilization, transfer and persistence of MGEs between and within 
bacterial genomes, play an essential role in adaptive bacterial processes and bacterial 
evolution (46, 114). Processes facilitated by MGEs contribute to the intra-species 
variability and the distribution of genetic modules, encoding virulence or antibiotic 
resistance determinants, within bacterial communities. During transduction and 
conjugation, a multitude of different MGEs, such as bacteriophages, transposons, 
insertion sequence (IS) elements, integrons and plasmids, may be transferred between 
bacteria. 
 The most simplistic transposon, an IS-element, consists of a transposase-
encoding gene surrounded by inverted repeated elements. A complex or composite 
transposon contains additional DNA, for example multiple antibiotic resistance genes 
flanked by two IS-elements. Transposases enable mobilization. Transposons may 
move within a genome, or between genomes, and cause high genome plasticity by 
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homologous recombination events (119). Integrons are genetic elements capable of 
capturing gene cassettes. Integrons are not mobile themselves, but may be 
incorporated into conjugative transposons. Super-integrons consisting of several gene 
cassettes and more than 60 different antibiotic resistance genes have been described 
(47). Insertion sequence common regions (ISCR) move genes through rolling-circle 
transposition, and are considered to be highly mobile genetic vehicles (120). ESBL-
encoding genes are frequently integrated in transposons, integrons or ISCR elements, 
carried and disseminated by plasmids (121).  
 
1.7.4 Plasmids 
Plasmids are extra-chromosomal, self-replicating, double-stranded DNA 
elements, harboured by most bacterial cells. They are diverse in size, mode of 
replication, mode of transmission and host range. Whereas broad-host range plasmids 
may spread among and be maintained by a wide range of bacterial hosts, narrow-host 
range plasmids are only maintained by closely related bacterial hosts. The plasmid 
backbone harbours conserved core genes essential for replication, transfer and 
maintenance (Figure 2). The replicon is a highly conserved region, which encodes 
genes needed for plasmid replication initiation and control (i.e. copy number). A 
plasmid may have one single or several compatible replicons (122). Plasmids may be 
conjugative, mobilizable or non-mobilizable. Conjugative, or self-transferable, 
plasmids carry a set of mobility genes and a membrane-associated mating pair 
formation, providing the mating channel. Some plasmids carry mobility genes, but use 
the mating channel of another plasmid, and are called mobilizable (123). The plasmid 
core genome may also encode plasmid-partitioning and post-segregational killing 
systems, ensuring the maintenance of a plasmid in a bacterial population after cell 
division (124). In their variable regions, plasmids frequently carry virulence and 
antibiotic resistance determinants (Figure 2). Thus, a plasmid may supply its host with 
favourable phenotypic traits, which may increase the survival of the host in a given 
environment (125, 126). 
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Figure 2. A simplified illustration of a typical IncF plasmid. The backbone/core regions include: 
replicons (yellow), transfer region (orange) and maintenance region (green). Variable regions (red and 
pink) are flanked by IS elements (blue). Undefined regions are grey. 
Evolutionary, plasmids are dynamic entities capable of adaptation to new 
environments and hosts by shearing and rearranging genetic elements. Thus, the 
variable regions of most plasmids are genomic mosaics of genes and MGEs that may 
continue to jump and rearrange within a plasmid, between plasmids and between 
plasmids and chromosomes due to changes in their environment. Plasmids were 
initially thought to cause a metabolic burden or fitness cost to their bacterial host 
(127). However, amelioration of initial costs or even increased fitness for bacterial 
hosts through compensatory evolution between host and plasmid, also in the absence 
of selective pressure, has been demonstrated in several studies (128-130).  
Historically, plasmids are classified based on plasmid incompatibility (131); i.e. 
the principle that plasmids with the same replicon type cannot be stably maintained by 
one host cell (132). Plasmid typing was traditionally performed by competition assays, 
where a new plasmid was introduced to an isolate carrying a plasmid of known 
incompatibility type (Inc type) (133). Today, a more convenient PCR-based replicon 
typing (PBRT) method has replaced the former competition assays (134). However, 
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due to the genetic plasticity of plasmids, two plasmids of the same Inc or replicon type 
may be very diverse in their variable regions.  
 
1.7.5 ESBL-plasmids 
Plasmids are considered effective vehicles for the spread of antibiotic resistance 
determinants. In Enterobacteriaceae, IncFII, IncA/C, IncL/M, IncN and IncI are among 
the most common plasmid types carrying ESBL-encoding genes. BlaCTX-M-15 is 
predominantly associated with the IncF family, but also IncR, IncI1, IncA/C, IncL/M 
and IncN type plasmids have been reported to carry blaCTX-M-15 (135-139). The IncF 
family consists of a heterologous group of narrow-host range low copy number 
plasmids, which vary in size from 50 to 200 kb. The host range of IncF plasmids is 
limited to the Enterobacteriaceae family. IncF replicons may be classified into IncFII, 
IncFIA, IncFIB and IncFIC. The IncFII replicon has been further subdivided into 
IncFIIS, IncFIIY and IncFIIK due to sequence variations and preferred host, Salmonella 
spp., Yersinia spp. and Klebsiella spp., respectively (140). In K. pneumoniae, IncFIIK 
plasmids have been associated with several clinical important ȕ-lactamases, including 
CTX-M-15, KPC-2, KPC-3 and NDM-1. In contrast to the rather clonal spread of 
blaKPC among K. pneumoniae ST258, blaCTX-M-15 seems to disseminate among 
unrelated K. pneumoniae clones (137, 141). IncFIIK plasmids carrying blaCTX-M-15 in K. 
pneumoniae have been associated with nosocomial outbreaks, indicating that this 
plasmid family may encode further phenotypic traits, which may increase the fitness 
and survival of their host in the hospital environment (20, 21, 142, 143). 
 
1.8 Epidemiology of ESBL-producing Enterobacteriaceae (ESBL-E) 
The overall prevalence of ESBL-producing Enterobacteriaceae (ESBL-E) in 
clinical isolates from Scandinavian countries is low compared to countries in the 
Southern and Eastern Europe (80, 81). Of notice, the ESBL-rates differ among 
Scandinavian countries, and the rates of invasive K. pneumoniae isolates resistant to 
3rd generation cephalosporins were considerably higher in Denmark (10-25%) 
compared to Norway and Sweden (1-5%) as reported by the European Antimirobial 
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Resistance Surveillance Network (EARS-Net) in 2012 (144). In Scandinavian 
countries, ESBLA-producing E. coli and K. pneumoniae are the most common ESBL-
producers detected in clinical samples, CTX-M-15 being the most prevalent enzyme 
(145-150). CTX-M-15-producing strains have also caused hospital outbreaks in 
Scandinavian countries (142, 151, 152).  
In Norway, the prevalence of ESBL-production among E. coli and K. 
pneumoniae blood culture isolates in 2012 was 5.5% and 2.9%, respectively (2). 
Although the ESBL-rates are still low, a 10-fold increase has been observed in 
Norwegian invasive E. coli and K. pneumoniae isolates from 2003 to 2012 (Figure 3).  
Figure 3. Prevalence of ESBL-production among Norwegian E. coli and Klebsiella spp. isolates from 
blood and urine 2003-2012 (Source: NORM/NORM-VET. 2012). Figure is reprinted with permission 
from NORM/NORM-VET.  
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The CTX-M-enzymes are the most common ESBLs also in Norwegian isolates, 
and constituted 60-80% of ESBLA detected in invasive Klebsiella spp. isolates from 
2009 to 2012 (Figure 4). ESBLM-C-enzymes are sporadically detected among human 
clinical isolates in Norway (153). However, high colonization rates (up to 43%) of 
ESBLM-C-producing E. coli have recently been detected among Norwegian broilers 
(154). Sporadic occurring ESBLCARBA-producing isolates are mostly associated with 
travel or previous hospitalization in countries outside Europe (155-157).  
Figure 4. ESBL-enzyme distribution in Norwegian Klebsiella spp. blood culture isolates from 2003 to 
2012 (Sources: NORM/NORM-VET. 2003-2012 and K-res). Figure is printed with permission from 
K-res. 
EARS-Net annually reports the proportion of resistance to 3rd generation 
cephalosporins, carbapenems, fluoroquinolones, aminoglycocides and other relevant 
antibacterial agents in invasive isolates of E. coli, K. pneumoniae, A. baumanii, P. 
aeruginosa, E.  faecalis/faecium, S. aureus and S. pneumoniae based on data from 30 
European countries. Figure 5 illustrates the increasing prevalence of resistance to 3rd
generation cephalosporins in European K. pneumoniae isolates from 2005 to 2012. In 
2012, the proportion of resistance to 3rd generation cephalosporins in invasive K. 
pneumoniae isolates varied from 1-5% in Norway, Sweden and Finland to >50% in 
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Greece and Eastern European countries. A similar geographical distribution of 
resistance to carbapenems in K. pneumoniae, and to 3rd generation cephalosporins and 
carbapenems in E. coli was reported (144). The geographical differences in the 
prevalence of MDR-strains within Europe may reflect more prudent use of 
antibacterial agents and more comprehensive infection control practices in the North 
and West of Europe, compared to the South and East (144).  
Figure 5. Proportion of 3
rd
 generation cephalosporins resistant invasive Klebsiella pneumoniae 
isolates in European countries in 2005 and 2012 (Source: ECDC/EARS-Net Maps, 
http://www.ecdc.europa.eu).
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Also outside Europe, the prevalence of ESBL-producing bacteria varies a lot 
between countries and continents, and from some areas data are still scarce. ESBLs are 
assumed to have emerged in Asia (158), and reports from Asia have documented 
alarming high prevalence of ESBL-producing MDR strains. In a recent study from  
India, ESBL-production was reported in 69% and 41% of clinical E. coli and K. 
pneumoniae isolates, respectively (159).  
Due to international tourism and migration, an influx of ESBL-producing MDR 
bacteria from high prevalence areas, like India, South East Asia and the Middle East, 
to low-prevalence areas, like Scandinavia, has been documented by several studies. A 
recent Swedish prospective study, revealed that 68/226 (30%) travellers with an 
ESBL-negative pre-travel sample acquired ESBL-E during travel outside Scandinavia. 
The most common species acquired was E. coli (90%) and the most common ESBL-
type was CTX-M (73%). The most important risk factors for ESBL-acquisition were 
travel to the Indian subcontinent, Asia and Africa North, as well as gastrointestinal 
symptoms (160). Similar results are reported from other travel studies performed in 
Sweden, Canada, Spain and the Netherlands, emphasizing the contribution of travel to 
the global distribution of ESBL-E (161-166). 
 
1.8.1 The CTX-M pandemic 
A number of review articles have addressed the rapidly emerging CTX-M-type 
ESBLs, which are now endemic in many European countries, in Asia and in South 
America (115, 167-173). Some CTX-M-enzymes have been associated with specific 
geographical areas; CTX-M-9 and CTX-M-14 are prevalent in Spain, whereas CTX-
M-2 is prevalent in South America (167, 174, 175). CTX-M-15, which was first 
detected in India in 2001 (176, 177), has spread to all continents (178). Both the 
dissemination of successful bacterial clones, such as E. coli ST131, and plasmid-
mediated spread of CTX-M-encoding genes, has contributed to the current situation 
(179). For the dissemination of some CTX-M-types, specific plasmid types seem to 
have played a major role. The spread of CTX-M-15 has been associated with IncFII 
plasmids (115). The early spread of CTX-M-3 in Poland and Eastern Europe was 
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facilitated by IncN plasmids (180). The more recent dissemination of CTX-M-14 in 
Spain and the UK seem to be favoured by IncK plasmids (181-184).  
The CTX-M family may be subdivided into five phylogenetic clusters: CTX-M 
group 1, CTX-M group 2, CTX-M group 8, CTX-M group 9 and CTX-M group 25, 
which differ from each other by 10% amino acid residues. The most common 
enzymes, CTX-M-15 and CTX-M-14, are found within CTX-M group 1 and 9, 
respectively (173). CTX-M-encoding genes have been detected in several 
Enterobacteriaceae species, such as Salmonella enterica, Shigella spp., Serratia 
marcescens and Proteus mirabilis (172, 173), but are most commonly found in E. coli 
and K. pneumoniae. More rarely, non-enterobacterial species, like P. aeruginosa, 
Acinetobacter spp., Vibrio spp., Aeromonas spp. and Stenotrophomonas maltophilia 
have been found to produce CTX-M-enzymes (173).  
Unlike the TEM- and SHV-type ESBLs, which evolved by selection of 
plasmid-mediated TEM- and SHV-type ȕ-lactamase mutants, the CTX-M-encoding 
genes are most likely captured from the environmental metagenome (173). 
Mobilization of blaCTX-M from the chromosome of Kluyvera ascorbata, K. cryocrecens 
and K. georgiana to plasmids has been described (185-187). Kluyvera belong to the 
Enterobacteriaceae family, but are rarely involved in human infection (188). Multiple 
gene capture events from different Klyuvera spp. likely explain the heterogeneity of 
the CTX-M family (173). CTX-M-encoding genes are mainly carried by conjugative 
plasmids in Enterobacteriaceae (172). More rarely, blaCTX-M has also been found 
integrated into the chromosome, as described in P. mirabilis (189). IS elements, such 
as ISEcp1 and ISCR1, are involved in the capture of blaCTX-M from the Kluyvera 
chromosome and its mobilization to plasmids (120, 190, 191). The ISs have, 
furthermore, been described to be strong promotors for high-level expression of 
blaCTX-M, conferring clinical resistance to the bacterial host (192, 193). ISEcp1 has 
been associated with all CTX-M-groups, and is likely the most relevant IS element in 
the capture and mobilization of CTX-M genes (172). The ISEcp1-blaCTX-M module has 
also been associated with IS26 (194) and Tn3-like transposons, frequently integrated 
in IncF plasmids (195).  
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Plasmids were also widely distributed among Enterobacteriaceae in the pre-
antibiotic era (196, 197). IncF plasmids are known to be well adapted to E. coli (198). 
The uptake of resistance genes into plasmids already well adapted within a bacterial 
population may be a key factor for the successful dissemination of resistance genes 
(117). It has been proposed that plasmid-mediated dissemination is the cornerstone of 
the current CTX-M pandemic (171). To better understand the dynamics of the 
pandemic, blaCTX-M-bearing plasmids must be carefully characterized and studied. 
New methods, such as full DNA sequencing, may shed new light on the dynamics of 
plasmid-mediated spread and persistence of resistance (199). 
 
1.9 Human ESBL-E carriage 
In humans, the intestine is the main reservoir for Enterobacteriaceae, and thus 
for ESBL-E. Intestinal colonization, moreover, normally precede Enterobacteriaceae 
infection (e.g. UTI), and is therefore of clinical interest (200-202). Grundmann et al. 
reported that only 15% of ICU infections were due to patient-to-patient transmission, 
(203), which underlines the importance of patients carrier states also when it comes to 
ESBL-E infection.  
The first reports on human faecal ESBL-carriage were from Spain. Mirelis et al. 
reported ESBL-carriage rates of 2.1% in stools from patients at hospital admission in 
2001, and a significant increase in carriage rates to 7.5% in 2002 (204). Valverde et al. 
reported an increase in faecal ESBL-carriage rates from 0.3% to 11.8% in hospitalized 
patients and from 0.7% to 5.5% in outpatients during the period 1991-2003. They also 
reported a faecal ESBL-carriage rate of 3.7% among healthy volunteers in 2003 (205). 
Since then, several studies have reported rates of intestinal ESBL-carriage in 
hospitalized patients, outpatients and among healthy volunteers in the community 
(206-215).  
Risk factors for being colonized by ESBL-E have been identified by several 
studies in different settings (160, 216-219). Tumbarello et al. identified recent 
hospitalization ( 12 months), transfer from another health care facility, comorbidity, 
recent ȕ-lactam or fluoroquinolone treatment ( 3 months), recent urinary 
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catheterization and age  70 years as risk factors for ESBL-E colonization in adult 
patients at hospital admission (220). 
1.9.1 ESBL-E carriage in the community 
Recently, Woerther et al. comprehensively reviewed the existing literature on 
carriage rates of ESBL-E among healthy subjects in the community. Based on data 
published between 2001 and 2011, they created a figure illustrating the ESBL-E 
carriage rates in six different geographic regions (according to the World Health 
Organization (WHO) region grouping) during this period (Figure 6 a). As illustrated 
by the figure, the Eastern Mediterranean and South East Asia showed the highest 
carriage rates and the most ascending trends of carriage (199). In some reports from 
Thailand and Egypt, ESBL-E carriage rates of 50-60% were documented (211, 221, 
222). In contrast, carriage rates reported from Europe did not exceed 12%, as reported 
in a study from Belgium (223). In all areas, ESBL-E carriage rates were increasing 
from 2001 to 2011, and CTX-Ms were the most prevalent ESBL-enzymes worldwide 
(199). Furthermore, the authors estimated the number of ESBL-E carriers in the six 
WHO areas for 2010. In South East Asia, over 1.1 billion ESBL-E carriers were 
estimated, whereas 35 million carriers were estimated in Europe (Figure 6 b).  
Figure 6. (a) ESBL-carriage rates in the community of the six WHO areas; based on data published 
between 2001 and 2011. (b) Estimated number of ESBL-carriers in the community of the six WHO 
areas in 2010; based on the data analysed in the review and the WHO 2010 population census (Source: 
Woerther et al., Clin Microbiol Rev 2013). Figures are reprinted with permission from Clinical 
Microbiology Reviews.  
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Due to the differences in the number of expected carriers between regions, the 
authors suggest poor access to drinking water, poverty and a high population density to 
be important driving forces for ESBL-E carriage and dissemination in the community 
(199). In low-prevalence countries, factors such as recent use of broad-spectrum 
antibiotics (e.g. ȕ-lactams and flouroquinolones) and travel to high endemic areas like 
Asia, the Middle East and North Africa, have been associated with increased risk of 
being colonized by ESBL-E (160, 217). More recently, ESBL-colonization in food 
animals and the possibility of ESBL-spread from animal to human via the food chain 
has been suggested to be an important factor for the dissemination of ESBL in the 
community (224-227). 
ESBL-E colonization among healthy children has not yet been well studied. 
However, in a recent Swedish study, the ESBL-E carriage rate in healthy preschool 
children was found to be 2.9% (9/313) (228). Similar ESBL-E carriage rates were 
reported among healthy children in Boliva, Peru and Portugal (229, 230). In a recent 
French study, 6.7% (28/419) of children in day-care centres were found to be ESBL-E 
carriers (231). Both the Swedish and the French study reported transmission of ESBL-
E among children attending the same preschool or day-care centre. The authors of the 
Swedish study suggest that crowding and insufficient hygiene standards in a preschool 
may have greater impact on transmission than a short course of penicillin or 
underlying medical conditions (228). 
 
1.9.2 Duration of ESBL-E carriage  
The duration of faecal ESBL-carriage has more recently been investigated in 
different settings.Various methods and study designs are used in these studies. Thus, 
the results may not easily be compared. Faecal carriage of ESBL-producing E. coli for 
up to 59 months was observed in 13% (5/39) of adult patients after a nosocomial 
outbreak in Sweden (232). In adult patients with traveller’s diarrhoea, who were also 
carriers of ESBL-producing E. coli, 24% (10/41) were ESBL-carriers 3-8 months after 
the first sample, and 7% (3/41) were still carriers after three years (233). A prospective 
follow-up study of 100 healthy adult Swedish travellers revealed that 24 had acquired 
ESBL-producing E. coli during travel outside Northern Europe, of which 24% (5/24) 
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were still colonized after six months (166). A French study reported mean duration of 
faecal ESBL-E carriage of nine months in 22 children adopted from Mali (234). A 
recent Swedish study reported faecal carriage of ESBL-producing E. coli or K. 
pneumoniae in 43% (26/61) of adult patients for 12 months after ESBL-related 
infections (235). Birgand et al. demonstrated that 39% (180/446) of patients were 
persistent ESBL-E carriers at readmission after previous ESBL-E infection or positive 
screening. The median time to ESBL-E clearance in these patients was 6.6 months 
(236). In a study from the Netherlands, the median time until ESBL-E clearance in 
adults after ICU discharge was 1.4 months (237).  
As described above, risk factors for being or becoming colonized by ESBL-E 
have been identified. Risk factors for prolonged ESBL-E carriage have until present 
only been studied in a few settings. Titelman et al. recently found that prolonged 
faecal ESBL-E carriage after ESBL-associated infection is associated with carriage of 
E. coli phylogroup B2 and CTX-M-group-9 (235). Birgand et al. concluded that 
prolonged ESBL-E carriage was associated with having the first positive ESBL-culture 
from a clinical sample, compared to having the first positive ESBL-culture recovered 
from a screening sample (236). Also risk factors for becoming colonized by ESBL-E 
during a NICU outbreak have been identified, as described in section 1.10. However, 
the duration of ESBL-E carriage and risk factors for prolonged carriage in children 
colonized during NICU hospitalization, have to our knowledge not yet been 
investigated.  
In contrast to healthy adults and older children, newborn children have not yet 
an established gut microbiota. The colonization, development and maturation of a 
child’s gastrointestinal tract begin at birth, and has been found to continue at least until 
five years of age (238). In particular, the early intestinal colonization process may be 
influenced by numerous factors, including mode of delivery, feeding regime, maternal 
diet and weight, probiotic use and antibiotic exposure. Infants hospitalized in NICUs 
are often exposed to several factors, which may alter the development and composition 
of their normal intestinal microbiota, and thus make them vulnerable to colonization 
by bacteria from the NICU environment (239-244). 
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1.9.3 Intra-household ESBL-E transmission 
Transmission of ESBL-E within households, however, has only been 
investigated in a limited number of studies. ESBL-E was detected in 27.4% (20/73) of 
household contacts (HCs) in a study from Spain, where adults with community-
acquired UTIs caused by ESBL-producing E. coli were index cases (218). A second 
Spanish study reported ESBL-E colonization in 16.7% (9/54) of HCs of persons with 
community-acquired ESBL-E infections (202). In a French study, intra-household 
transmission was suspected in 23% (5/22) of HCs of adoptive children from Mali 
colonized with ESBL-E (234). In a study from Hong Kong, a CTX-M carriage rate of 
43.5% was found in children (0-5 years of age) upon hospital admission. In 83% 
(44/53) of their respective households, at least one HC was also colonized by a CTX-
M-producing strain. The number of HCs colonized within a household was inversely 
correlated with the living space per person (215).  
 
1.10 Nosocomial outbreaks 
An outbreak or an epidemic may be defined in different ways. The World 
Health Organisation definition of an outbreak is: “A disease outbreak is the occurrence 
of cases of disease in excess of what would normally be expected in a defined 
community, geographical area or season. An outbreak may occur in a restricted 
geographical area, or may extend over several countries. It may last for a few days or 
weeks or for several years” (245). Tacconelli et al. recently defined an epidemic or 
outbreak of MDR Gram-negative bacteria as following: “Settings where there is an 
unusual or unexpected increase of cases of infections due to MDR-GNB (Gram-
negative bacteria) already isolated in the hospital or an emergence of cases of infection 
due to a new MDR-GNB, with or without molecular analysis of strains” (246). 
S. aureus, including MRSA, and MDR Gram-negative bacteria are frequently 
associated with nosocomial (i.e. hospital associated) outbreaks. Klebsiella spp., 
Staphylococcus spp., Serratia spp. and Enterobacter spp. are the pathogens most 
frequently involved in NICU outbreaks, whereas Staphylococcus spp., Pseudomonas 
spp. and Acinetobacter spp. more often cause outbreaks in adult ICUs (247). 
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Outbreaks caused by MDR bacteria are generally more common in ICUs than in other 
hospital wards. ICU patients are often immunocompromised and susceptible to 
colonization by bacteria from the hospital environment. Furthermore, broad-spectrum 
antibiotics and invasive procedures are frequently used in ICUs. Invasive equipment, 
such as bronchoscopes, has been reported to be the source of patient-to-patient 
transmission of outbreak strains (248-250).  
ESBL-producing K. pneumoniae has become a common cause of nosocomial 
outbreaks, especially in NICUs (251-256). Factors, such as overcrowding, 
understaffing, insufficient hygienic barriers and frequent use of broad-spectrum 
antibiotics, often facilitate the dissemination of MDR strains in NICUs and between 
NICU patients (257). Risk factors for ESBL-colonization during a NICU outbreak, e.g. 
low gestational age, low birth weight, use of invasive devices, antibiotic treatment and 
prolonged hospital stay, have been identified by several studies (253, 258-260). The 
gastrointestinal tract of patients is an important reservoir for ESBL-E (261), and 
transient hand carriage of ESBL-producing K. pneumoniae among HCWs has been 
reported to be one of the most common mechanisms of ESBL-transmission between 
infants during NICU outbreaks (251, 262-264).  
Gastmeier et al. reviewed NICU outbreaks reported in the worldwide database 
of health-care associated outbreaks, and found that Klebsiella spp. caused 20.3% of 
NICU outbreaks (25% of these were caused by ESBL-producing Klebsiella spp.), that 
BSI was the most frequent type of infection during NICU outbreaks (67.7%), and that 
the overall mortality in NICU outbreaks was 6.4%. In outbreaks associated with 
Klebsiella spp., the mortality was 11.8% (247). 
 
1.10.1 Outbreak prevention and control 
Efficient and targeted interventions are crucial to reduce the spread of ESBL-E 
and to prevent and control outbreaks. Recently, Tacconelli et al. proposed guidelines 
for the management of infection control measures to reduce the transmission of MDR 
Gram-negative bacteria among adult hospitalized patients (246). In an outbreak caused 
by ESBL-E, the authors strongly recommend the implementation of enhanced hand 
hygiene, educational programmes, active screening cultures, contact precautions and 
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isolation of colonized patients in single rooms, the use of alert codes to identify 
previously colonized patients at readmission, environmental cleaning and 
antimicrobial stewardship. Cohorting of patients and staff, environmental screening 
and screening of HCWs are considered conditional interventions. In an outbreak 
associated with MDR K. pneumoniae, also cohorting of staff was strongly 
recommended in these guidelines (246). The combination of screening cultures, 
contact precautions for colonized and infected patients, and antimicrobial stewardship 
have been reported to be of significant importance to reduce the ESBL incidence, also 
in non-outbreak settings (265). In a recent Danish multidisciplinary intervention study, 
including isolation precautions, communication, education, antimicrobial stewardship 
and restrictions, the incidence of infections caused by ESBLA- and ESBLM- producing 
K. pneumoniae successfully decreased in the study period (266). 
Educational programs to enhance hand hygiene among HCWs, is strongly 
recommended to prevent and control the spread of MDR Gram-negative bacteria in 
hospitals, both in the endemic and epidemic setting (246). The need for strict contact 
precautions and isolation of colonized patients in single rooms depends on the 
characteristics of the colonizing microbe and the risk for spread, and of course differs 
between wards and patients characteristics. In ICUs or other wards with 
immunocompromised patients, isolation of colonized patients should always be 
considered (246, 267).  
In most reported NICU outbreaks, multiple infection control measures, such as 
patient screening, enforced hand hygiene, cohorting of patients and protective 
clothing, were implemented. In 16.3%, the NICU had to be closed to control the 
outbreak (247). 
 
1.10.2 ESBL-screening 
Tacconelli et al. strongly recommend the implementation of active screening 
cultures in the epidemic setting to reduce the spread of MDR Gram-negative bacteria 
(246). ESBL-screening of patients upon hospital admission and during hospitalization 
in non-outbreak situations has been debated. Retrospective studies indicate that 
screening at hospital admission might reduce the rate of hospital-acquired ESBL-
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infections (265, 268-270). To further address this issue, prospective studies and cost-
benefit analysis are needed (270). 
Although PCR-based methods are available, culture-based methods are the most 
reliable and most used methods for ESBL-screening. Several in-house and commercial 
selective media are available for ESBL-screening (e.g. Chrom ID ESBL and Brilliance 
ESBL) (271). Rectal surveillance swabs, as well as clinical urine, respiratory and 
wound samples are considered appropriate for ESBL-E screening (246). In a study 
assessing the sensitivity of six different anatomic sites (groin, perirectal area, finger 
webs, forehead, axillae, toe webs), the groin and the perirectal area were the most 
sensitive sites for detecting MDR Gram-negative bacteria, including ESBL-producing 
K. pneumoniae (272). Whereas one screening site, e.g. the perirectal area, is 
considered sufficient for ESBL-E detection, multiple sites should be cultured in order 
to detect MDR A. baumannii colonization (246). In a recent study, Snyder et al. 
detected the same MDR Gram-negative strain by perianal/rectal swabbing as also 
detected in clinical samples in 29/37 patients (273), thus concluding with a sensitivity 
of 78% of perianal/rectal surveillance swabs for the detection of colonization with 
MDR Gram-negative bacteria. 
 
1.10.3 Molecular outbreak investigations 
Molecular examination of epidemiological links between patients and wards, 
and identification of the outbreak strain(s) and the source, are important for successful 
outbreak prevention and control. Outbreaks caused by MDR Gram-negative bacteria 
may be clonal or multiclonal. K. pneumoniae has been found to spread efficiently by a 
clonal mode in the nosocomial setting, e.g. via HCWs hands (274). However, 
multiclonal K. pneumoniae outbreaks due to interclonal or intergenus dissemination of 
promiscuous MDR plasmids have also been described (275, 276). “Plasmid-borne” 
outbreaks may be difficult to identify, and thus remain undetected. Therefore, 
molecular typing both on strain and plasmid level is needed in order to detect and 
confirm epidemiological links between bacterial isolates and patients during an 
outbreak.  
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Currently, some of the most common methods used for typing of 
Enterobacteriaceae strains during an outbreak situation are pulsed-field gel 
electrophoresis (PFGE) and multiple-locus variable number tandem repeat analysis 
(MLVA) (277). Also in-house and commercial PCR-based typing methods, such as the 
DiversiLab system (bioMèrieux), are increasingly used for strain typing during 
outbreaks (278). Brolund et al. compared the discriminatory power of the DiversiLab 
system to PFGE on a collection of ESBL-producing E. coli and K. pneumoniae 
isolates, and concluded that the DiversiLab system may be useful as a primary 
screening method in an outbreak situation, but the results should be confirmed by 
PFGE (279). Multilocus sequence typing (MLST) does not have as high 
discriminatory power as the above mentioned methods, and is therefore more 
convenient for epidemiological surveillance than in local outbreak situations. More 
recently, whole genome sequencing (WGS) has been successfully applied for tracking 
both food-borne outbreaks in the community and hospital outbreaks (280, 281).  
For plasmid profiling and typing, S1-PFGE, restricted fragment length 
polymorphism (RFLP) and PBRT are commonly used. However, WGS may become 
an important tool also for plasmid detection and typing in the near future. Brolund et 
al. described how they used WGS to analyse the plasmidome (i.e. the plasmid-content) 
of ESBL-producing E. coli strains, and concluded that their approach of analysing 
WGS data could become a valuable tool for tracing plasmids in an outbreak situation 
(282). Recently, Carattoli et al. suggested an approach for in silico detection and 
typing of plasmids in Enterobacteriaceae using WGS data (283). 
 
1.11 ESBL-E: clinical impact 
Enterobacteriaceae are common causes of both community-acquired and 
nosocomial infections (80). Whereas CTX-M-producing E. coli has spread efficiently 
in the community and frequently causes community-acquired infections (82), MDR K. 
pneumoniae has become one of the most dreaded organisms in the hospital setting 
(284). ESBL-E strains often express co-resistance to several commonly used antibiotic 
classes, such as the fluoroquinolones, aminoglycosides and trimethoprim-
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sulfamethoxazole. Thus, the treatment options are often very limited in infections 
caused by these bacteria. In infections caused by MDR ESBLCARBA-producing strains, 
there may be no effective treatment options at all. High resistance rates against drugs 
commonly used in the empirical treatment of critically ill patients may result in initial 
treatment failure, delay of adequate therapy and increased morbidity and mortality 
(285, 286). Furthermore, ESBL-E associated infections has been found to be a burden 
on the health care system, conferring prolonged hospital stay and increased costs 
(287). 
Also in uncomplicated ESBL-E infections, such as community-acquired lower 
UTIs, empirical treatment often fails. In some cases, the causative agent confers 
resistance to all per oral drugs. Failure of empirical therapy of an otherwise 
uncomplicated UTI may result in a complicated UTI or BSI, which in turn requires 
hospitalization and intravenous drug administration. In Norway, however, the 
sensitivity rates to per oral drugs, such as nitrofurantoin and pivmecillinam, are still 
high among E. coli urine isolates (99.0% and 95.8%, respectively) (2). Especially 
pivmecillinam play an important role in the treatment of lower UTIs in Scandinavian 
countries, and is about to be “rediscovered” also in other countries, for example in the 
UK (288). The clinical outcome of pivmecillinam treatment in uncomplicated UTI, 
caused by ESBL-E, has been debated. A recent Norwegian study reported treatment 
failure of pivmecillinam in 44% of patients with UTI caused by ESBL-producing E. 
coli (289), whereas the authors of a recent Danish study concluded that pivmecillinam 
was bacteriologically and clinically effective for the treatment of lower UTIs caused 
by ESBL-E (290). Of notice, different dosing regimens are used in Norway and 
Denmark, 200 mg three times a day and 400 mg three times a day, respectively. 
Moreover, in a recent British study, concern about increasing resistance to 
pivmecillinam in ESBL-E was raised (291). 
In order to make successful recommendations for empirical treatment, 
knowledge of the local epidemiology and levels of resistance are crucial. International 
and national surveillance of resistance, as performed by EARS-Net and 
NORM/NORM-VET (Usage of Antimicrobial Agents and Occurrence of 
Antimicrobial Resistance in Norway), is of great importance. Hence, even if the 
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empirical treatment guidelines are based on the local epidemiology and surveillance 
data, it may fail. We do not know when the “superbugs” attack, even in areas with low 
levels of resistance. Traditional species identification and subsequent AST usually 
takes 48-72 hours, and we therefore have to rely on empirical guidelines before final 
AST-results are available. As resistance is emerging, the development of more rapid 
methods for detection of an antibiotic resistant geno- and/or phenotype in clinical 
isolates is of significant importance (98, 100). Also WGS was recently proposed to be 
a future approach for rapid species identification and detection of resistance (292, 
293). 
 
1.12 Summary of the introduction 
AMR is emerging rapidly among Gram-negative bacteria. In particular, the 
emergence of plasmid-mediated ESBL-production in E. coli and K. pneumoniae 
causes great concern. ESBL-producing K. pneumoniae may cause community and 
hospital infections, and is increasingly reported to cause nosocomial outbreaks, 
especially in the NICU setting.  
NICU outbreaks may have fatal consequences for affected patients. Only a 
small proportion of NICU outbreaks have been reported, although insight into the 
nature of NICU outbreaks is of importance for the improvement of outbreak 
prevention and control (247). Thus, we decided to investigate and describe the most 
important aspects of the ESBL-outbreak affecting the NICU at Stavanger University 
Hospital during 2008-09, including the extent and the source of the outbreak, infection 
control measures needed to control the outbreak and the characteristics of the K. 
pneumoniae outbreak strain.  
Children colonized during the outbreak were putative faecal carriers of ESBL-
producing K. pneumoniae when discharged from the hospital to their homes. As 
limited knowledge existed concerning the duration of faecal ESBL-E carriage and the 
risk of ESBL-E transmission within households, a follow-up study of colonized 
children and their families was initiated to address these to date unanswered questions.  
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The dynamics between an antibiotic resistance plasmid and its host bacteria 
have to our knowledge not yet been studied during human carriage. The collection of 
bacterial isolates obtained during the outbreak and the follow-up study, gave us the 
opportunity to study the dynamics between an ESBL-encoding plasmid and its K. 
pneumoniae host strain during long-term intestinal colonization in young children. 
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2 Aims of the Thesis  
 
The overall aim of this thesis was to gain new insights into ESBL-E outbreak 
dynamics and control in the NICU setting, the colonization dynamics between an 
ESBL-producing K. pneumoniae strain and its newborn human host, and the dynamics 
between a K. pneumoniae outbreak strain and its ESBL-encoding plasmid.  
 
The specific objectives were: 
I. To describe the characteristics of the NICU outbreak at Stavanger University 
Hospital caused by ESBL-producing K. pneumoniae (ESBL-Kp) 
a. To determine the extent and the source of the outbreak  
b. To describe implemented infection control measures 
c. To examine the microbiological and molecular properties of the outbreak 
strain(s) 
 
II. To investigate the ESBL-Kp dynamics during intestinal carriage in children 
colonized during the NICU outbreak, after discharge from the hospital 
a. To determine the duration of ESBL-Kp carriage in colonized children 
b. To identify risk factors associated with prolonged ESBL-Kp carriage  
c. To determine the rate of intra-household transmission of ESBL-Kp 
 
III. To identify and characterize the ESBL-encoding plasmid of the K. pneumoniae 
outbreak strain(s) 
a. To obtain the complete DNA sequence of the ESBL-encoding plasmid 
b. To identify plasmid-encoded traits relevant for the outbreak dynamics 
c. To investigate the dynamics between the plasmid and its K. pneumoniae 
host with respect to self-transfer, maintenance and fitness cost during 
intestinal colonization in a human host (i.e. colonized children)  
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3 Material and methods 
3.1 Setting 
Stavanger University Hospital serves a population of 330.000 inhabitants 
(2010) and has about 5000 deliveries annually. The 21-bed NICU treats neonates from 
gestational age 23 weeks, and has approximately 550 admissions and 7000 patient-
days per year. The unit has four adjacent rooms, including one isolation room. The 
NICU serves as a secondary referral center for a local hospital (with 1500 deliveries 
annually). Patients in need of surgery are transferred to Oslo University Hospital.  
 
3.2 Study design 
This thesis is based on three sub-studies: The first sub-study, “The NICU 
outbreak”, is a retrospective descriptive study of the ESBL-Kp associated NICU 
outbreak at Stavanger University Hospital during 2008-09 (Paper I). The second sub-
study, “The follow-up study”, is a prospective cohort study including children 
colonized during the outbreak and their families (Paper II). The third sub-study, “The 
plasmid study”, is based on in vivo and in vitro studies of the ESBL-encoding plasmid 
in K. pneumoniae isolates collected during the outbreak and the follow-up study 
(Paper III). 
 
3.2.1 Subjects and bacterial isolates 
An outbreak was suspected in late January 2009, as ESBL-Kp was detected in 
clinical samples from three NICU patients during one week. All children hospitalized 
in the NICU from 30 January to 15 April were screened for ESBL-Kp colonization 
(n=117). Furthermore, all children discharged from the NICU during November 2008 
until the end of January 2009 were offered screening, and 127/135 children were 
screened. In addition, all children admitted to or discharged from the maternity wards 
during the outbreak period were offered screening if exposed to cross-contamination, 
and 247/872 children were screened. Altogether, 501 children underwent screening for 
ESBL-Kp during the outbreak investigations (Figure 7).  
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Figure 7. Simplified study design. 
A-NICU=screened when admitted to the NICU; D-NICU=screened after dicharged from the NICU; 
MW=screened when admitted or discharged from the maternity wards; HE=screening samples from 
the hospital environment; HCWs=rectal samples from health care workers; BM=breast milk samples 
from n mothers of colonized children; HCs= household contacts; HHs=households 
 
 
Included in the outbreak investigations were also environmental screening, 
screening of HCWs and screening of breast milk samples from mothers of colonized 
children. In total 502 screening samples were taken from the NICU environment and 
medical equipment. All HCWs in the NICU were offered anonymous screening, and 
30/80 HCWs participated. Finally, breast milk samples from 18/54 mothers of 
colonized children were screened (Figure 7). Sampling for ESBL-screening was 
performed as described in 3.2.2. 
During the NICU outbreak, 58 children were found colonized by ESBL-Kp, i.e. 
CTX-M-15-producing K. pneumoniae (CTX-M-15-Kp). One of the colonized children 
died. Thus, 57 children from 53 households (twins in four families) and their HCs (i.e. 
parents and siblings) were invited to participate in a follow-up study. The intended 
study period was one to three years after hospital discharge (or until CTX-M-15-Kp 
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elimination in the invividual colonized child). A total of 52/57 (92%) children from 48 
households and 70/101 (69%) HCs from 33 households were included in the follow-up 
study. One infant and ten HCs were excluded (see exclusion criteria below) during the 
study period. Thus, follow-up data from 51 children (25 boys and 26 girls) from 47 
households and 60 HCs (28 mothers, 25 fathers and 7 siblings) from 28 households 
were considered in this study (Figure 7). Seven of the 51 children had not been 
admitted to the NICU, but were likely colonized by cross-transmission in the maternity 
wards. Two children had most of their NICU stay in another hospital. Demographic 
data of the 42 children hospitalized and colonized in the NICU in our hospital are 
listed in Table 3.  
Table 3. Demographic data of children colonized in the NICU (n=42).
Variables 
Male gender 22 (52)a
Gestational age (weeks) 34 (30-37)b
Birth weight (g) 2055 (1226-2969)b
Length of hospital stay (days) 19 (10-61)b
Treated with antibiotics* 33 (79)a
Length of antibiotic treatment* (days) 5 (3-7)b
Caesarean section 24 (57)a
Total parenteral nutrition 16 (38)a
aNumber (%); bMedian (IQR); *Ampicillin and gentamicin intravenously 
All putative ESBL-Kp isolates recovered during the NICU outbreak and the 
follow-up study were phenotypically characterized (as described in 3.4). A selection of 
152 ESBL-Kp isolates was subjected to molecular characterization (as described in 
3.5). Of these, 60 isolates were recovered during the outbreak: the first screening 
isolate obtained from all colonized children (n=58), one blood culture isolate 
recovered from one infected child (n=1), and the first breast milk isolate from the 
mother of the index case (n=1). And 92 isolates were recovered during the follow-up 
study: the last follow-up isolate from all children (1/51 children had no positive 
follow-up sample) (n=50), an additional follow-up isolate from children colonized > 
12 months (n=23), the first screening isolate from 12 HCs colonized during the follow-
62 
 
up study (n=12) and the last follow-up isolate from seven HCs (5 colonized HCs had 
no positive follow-up sample) (n=7).  
Finally, a selection of nine CTX-M-15-Kp isolates and one CTX-M-15-
producing E. coli isolate, recovered during the outbreak and the follow-up study, was 
included in the plasmid study: the first and the last faecal CTX-M-15-Kp isolate from 
four children colonized for 18-24 months (n=8), the first CTX-M-15-Kp breast milk 
isolate from the mother of the index case (n=1) and one CTX-M-15-producing E. coli 
isolate recovered from one child during follow-up (n=1) (Figure 7). 
 
3.2.2 ESBL-screening 
During the outbreak investigations, all children hospitalized in the NICU were 
repeatedly screened for ESBL-Kp colonization by faecal or rectal swabbing. From the 
children hospitalized in the NICU as the outbreak was detected (n=24), additional 
swab samples were collected from nasopharynx and conjunctiva. Only one faecal 
screening sample was obtained from discharged children. HCWs were screened once 
by rectal swabbing (four months into the outbreak). One or more breast milk samples 
from mothers of colonized children were screened if available (if mothers were 
donating their breast milk to other infants, screening was required). Environmental 
samples were repeatedly collected from, e.g. sinks, bath tubes, breast milk pumps, the 
milk kitchen, respiratory therapy equipment and incubators.  
During the follow-up study, faecal and rectal swab samples were obtained from 
colonized children and their HCs, respectively (for details, see Appendix 1). The 
intended sample schedule included a monthly sample from the children and their HCs 
during the first year, and thereafter every three months (for up to three years after 
hospital discharge). Home sampling was performed by the parents, and the samples 
were sent by post to the lab. All screening samples (except breast milk samples) were 
collected using sterile cotton-tipped swabs (COPAN®) and transported in Stuart’s 
medium. All samples were subjected to culture-based ESBLA-screening as described 
in 3.4.  
  
63 
 
The following were excluded from the follow-up study:  
- Children providing less than three follow-up samples. 
- HCs that did not provide follow-up samples regularly until elimination of CTX-
M-15-Kp from their respective colonized child. 
- Children colonized in the maternity wards, or hospitalized in another NICU 
before transferred to our NICU, were excluded from the risk analysis. 
 
3.2.3 Definitions 
• CTX-M-15-Kp colonization: Identification of CTX-M-15-Kp in faecal or 
rectal samples from children without clinical symptoms or signs of systemic 
infection (The NICU outbreak).  
• Systemic CTX-M-15-Kp infection: Isolation of CTX-M-15-Kp from clinical 
samples (blood or cerebrospinal fluid) from children with symptoms or signs of 
systemic infection (The NICU outbreak). 
• CTX-M-15-Kp elimination: Three or more consecutive negative faecal 
samples (screening interval  month) in previously colonized children (The 
follow-up study) 
• Intra-household transmission: Identification of CTX-M-15-Kp in rectal 
samples of HCs (The follow-up study). 
 
3.2.4 Clinical data and questionnaires 
Date of birth, admission and discharge were recorded for all children admitted 
to the NICU or maternity wards during the period from November 2008 to April 2009 
(The NICU outbreak). For the risk analysis, data concerning gender, gestational age, 
birth weight, mode of delivery, length of hospital stay, mode of nutrition and antibiotic 
treatment during hospitalization (Table 3) were obtained from medical records of 
children hospitalized in the NICU during the outbreak (The follow-up study). 
Questionnaires were answered by the parents and returned together with 
screening samples during the follow-up study. Information concerning nutrition, 
infections, re-hospitalization and use of antibiotics in the children after hospital 
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discharge was obtained. Furthermore, information about travel outside Scandinavia 
was recorded for all household members during the study period (Appendix 2). 
  
3.3 Ethical considerations 
The study was approved by the Norwegian Data Inspectorate and the Regional 
Committee on Medical Research Ethics (096.09). The Regional Committee on 
Medical Research Ethics also approved the extension of the follow-up period from one 
to three years. Signed statements of informed consent were obtained from one or both 
parents on behalf of participating children and from all participating parents. In this 
study no interventions or procedures were performed, which could have posed any risk 
to the participants. 
 
3.4 Phenotypical detection of ESBLA-producing isolates  
Culture-based ESBLA-screening 
All screening samples were inoculated on modified MacConkey agar with a 30 
μg cefotaxime tablet (Rosco Diagnostics AS, Taastrup, Denmark) and on Chrom ID 
ESBL agar (bioMèrieux, Marcy l’Etoile, France) for ESBLA-screening. To potentially 
increase the sensitivity during the follow-up study, swabs were also cultured in brain 
heart infusion (BHI) broth (Becton Dickinson, Sparks, Maryland, USA) supplemented 
with cefotaxime (1mg/L) directly after plating. Agar plates and broth samples were 
incubated for 24-48 h at 35°C. Any putative ESBL-producing strain (one colony of 
each phenotype) growing on the Chrom ID ESBL agar was sub-cultured on modified 
MacConkey agar for further identification. Colonies growing within the cefotaxime 
inhibition zone on the primary modified MacConkey agar were sub-cultured if no 
growth was detected on the Chrom ID ESBL agar after 48 h of incubation. Bacterial 
growth outside the cefotaxime inhibition zone was used as a control for a valid sample. 
If no growth of ESBL-producing bacteria was suspected on either of the two plates 
after 48 h of incubation, the corresponding BHI broth sample was re-inoculated on a 
65 
 
Chrom ID ESBL plate (The follow-up study). K. pneumoniae ATCC 700603 (ESBL-
positive) and E. coli ATCC 25922 (ESBL-negative) were used as control strains. 
 
Antimicrobial susceptibility testing (AST) and species identification 
 AST was performed by agar disk diffusion (Becton Dickinson) on all putative 
ESBLA-producing isolates. MICs to relevant antibiotics (e.g. mecillinam, 
nitrofurantoin, piperacillin-tazobactam, ciprofloxacin, gentamicin, tobramycin, 
trimethoprim-sulfamethoxazole, cefotaxime, ceftazidime, cefepime, aztreonam and 
meropenem) were determined by Etest (bioMérieux) on selected isolates. 
Interpretations were according to clinical breakpoints recommended by the Norwegian 
Working Group on Antibiotics 2009-2011 (294), which were in line with the EUCAST 
recommendations for the same period (295). An ESBLA-phenotype was confirmed by 
the double disk approximation test and by the combined disk method using 
cefotaxime/cefotaxime-clavulanate and ceftazidime/ceftazidime-clavulanate discs 
(96). ESBLA-producing isolates were identified to the species level using Vitek2 ID-
GN (bioMèrieux). All ESBLA-producing isolates were stored at -70°C for subsequent 
molecular analysis. 
 
3.5 Molecular characterization of ESBLA-producing isolates 
Detection of ESBLA-encoding genes 
Screening for the ESBLA-encoding genes blaSHV, blaTEM and blaCTX-M was 
performed by PCR as previously described (99). BlaCTX-M-15 was detected by using 
blaCTX-M-group1-specific primers (296, 297) and subsequent DNA sequencing of the PCR 
products using the Genetic analyser 3130 (Applied Biosystems, Foster City, CA, 
USA). Editing and alignments of DNA sequences were performed using SeqScape 
version 2.5 (Applied Biosystems). 
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Bacterial strain typing 
Clonal relatedness was examined by PFGE of XbaI-digested (New England 
BioLabs, Ipswich, UK) genomic DNA using the Chef-DR® III System (BioRad, Oslo, 
Norway). Briefly, PFGE was run at 12°C, with pulse time 1-20 s, at 6 V/cm on a 120° 
angle in 0.5xTBE buffer for 21 h. PFGE-patterns were analysed and compared in 
BioNumerics version 6.6 (Applied Maths NV, St-Martens-Latem, Belgium), and 
results were interpreted according to the criteria of Tenover et al. (298).  
One representative isolate per PFGE-type was subjected to MLST. MLST of 
seven K. penumoniae housekeeping genes was performed as described by Diancourt et 
al. (299). 
 
Detection of virulence determinants in K. pneumoniae 
One representative isolate per PFGE-type was subjected to screening for K-
types commonly associated with invasive disease (K1, K2, K5, K20, K54, K57) and 
virulence genes common in invasive K. pneumoniae isolates (rmpA, wcaG and allS). 
Screening was conducted by PCR as described (11, 14). 
 
3.6 Plasmid analyses 
Plasmid typing and profiling 
Plasmid replicons of CTX-M-15-producing isolates were detected by PCR 
using a commercial kit (DIATHEVA, Fano PU, Italy) developed by Carattoli et al. 
(134, 140). Plasmid profiling was performed by PFGE of S1-nuclease (Promega, 
Madison, WI, USA) digested total DNA (296, 300). Briefly, PFGE was run in the 
Chef-DR® III System (BioRad) at 14°C, with pulse time 1-20 s, at 6 V/cm on a 120° 
angle in 0.5xTBE buffer for 15 h. Each band on the gel was considered a linearized 
plasmid. The Low range ladder (New England BioLabs) was used as a plasmid size 
marker. Plasmid DNA bands were transferred to positively charged nylon membranes 
using a vacuum blotting system (Vacuum Blotter, Model 785, BioRad). CTX-M-15-
encoding plasmids were identified through Southern blot-hybridization with blaCTX-M-
specific probes. The replicon types of both CTX-M-15-encoding plasmids and 
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additional plasmids were determined through hybridization with probes specific for 
detected replicons. The DIG High Prime DNA Labelling and Detection Starter Kit I 
(Roche Diagnostics, Mannheim, Germany) was used for labelling of PCR-generated 
probes and detection.  
 
Plasmid sequencing   
Plasmid DNA from one CTX-M-15-Kp isolate (Kp848) was purified using the 
Qiagen large construct kit (Qiagen). A shotgun library was constructed and single-end 
pyrosequencing reads were obtained applying the 454 Genome Sequencer FLX-system 
(Roche Diagnostics, Indianapolis, IN, USA). Reads were assembled de novo using the 
Newbler software (Roche Diagnostics). Gap closure was performed by sequence-based 
bridging. Artemis version 15 (Welcome Trust Sanger Institute, Hinxton, UK) was used 
for alignment and annotation. Plasmid sequence comparison with previously published 
plasmids was performed using WebAct and ACT version 12 (Welcome Trust Sanger 
Institute). Plasmid MLST (pMLST) was performed as proposed by Villa et al. (140) 
using the pMLST version 1.2 of the Center for Genomic Epidemiology (Lyngby, 
Denmark) (301). 
 
Plasmid transfer 
In vivo: To detect possible self-transfer events of the CTX-M-15-encoding 
plasmid from CTX-M-15-Kp to other Enterobacteriaceae strains during intestinal 
colonization, all CTX-M-15-producing isolates, other than CTX-M-15-Kp, recovered 
during follow-up of 49 children (n=1) were characterized by PBRT, S1-nuclease 
PFGE and Southern blot-hybridization as described above.  
In vitro: Transferability of the CTX-M-15-encoding plasmid from CTX-M-15-
Kp to a rifampicin resistant plasmid-free recipient strain, E. coli J53-2, was 
investigated by broth mating as follows: strains were cultured ON in Luria Bertani 
(LB) broth (Sigma Aldrich, Oslo, Norway) at 35°C, ON cultures were diluted 1:100 
and incubated until reaching the logarithmic growth phase (measured by OD600nm of 
~0.5). Donor and recipient cultures were mixed 1:9 and incubated at 35°C with careful 
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shaking. After 4 h and 24 h of incubation, aliquots of 100 μL mixed culture were 
plated on LB plates (Sigma Aldrich) containing cefotaxime (2 mg/L) and rifampicin 
(100 mg/L). The clinical K. pneumoniae strain, Kp2200, containing a self-transferable 
IncI1 CTX-M-15-encoding plasmid was used as control. Furthermore, re-
transferability of the CTX-M-15-encoding plasmid was tested by filter mating between 
CTX-M-15-Kp and corresponding rifampicin resistant plasmid-free segregant isolates 
(i.e. CTX-M-15-Kp isolates that lost the CTX-M-15-encoding plasmid during serial 
transfer; see below) under the following conditions: ON cultures were diluted 1:1000, 
mixed 1:1 and spotted in 40 ȝL droplets on LB plates. After 8 h of incubation at 37°C, 
cell lawns were scraped off, re-suspended in phosphate buffered saline (PBS) and 
plated on LB plates supplemented with cefotaxime (8 mg/L) and rifampicin (100 
mg/L). 
 
Plasmid stability  
In vivo: To detect CTX-M-15-Kp isolates that possibly had lost the CTX-M-15-
encoding plasmid during intestinal colonization, the two first ESBL-negative faecal 
follow-up samples from 35/49 children were screened for ESBL-negative isogenic K. 
pneumoniae strains (i.e. in vivo segregants devoid of the CTX-M-15 phenotype). 
Frozen ESBL-negative samples were inoculated on modified McConcey agar and 
incubated ON at 35°C. On the next day, all Gram-negative strains detected were 
identified to the species level by MALDI-TOF MS (Bruker Daltonics, Bremen, 
Germany), and subsequently all K. pneumoniae isolates (n=24) were subjected to 
typing by XbaI-PFGE as described above. 
In vitro: The in vitro stability of the CTX-M-15-encoding plasmid in CTX-M-
15-Kp was investigated by serial passage of two independent populations of eight 
ancestor isolates (the first and the last isolate from the four children colonized the 
longest) for ~two months at 37˚C without antibiotic selection. Twice a day, aliquots of 
10 ȝl were serially transferred into 1 ml of fresh LB broth, allowing ~6.64 generations 
per transfer. At the endpoint of the experiment, 150 ȝL aliquots from 10-5-dilutions of 
the 16 evolved populations were plated on plain LB plates and incubated at room 
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temperature ON. To determine the rate of plasmid-free segregants (i.e. CTX-M-15-Kp 
colonies devoid of the CTX-M-15-encoding plasmid and thus the CTX-M-15 
phenotype) in each sample, 120 colonies were randomly picked from each plate and 
streaked on plain LB plates and on LB plates supplemented with cefotaxime (8 mg/L) 
in parallel. A selection of putative segregants (at least one representative per ancestor 
isolate) were further analysed by relevant gradient tests (Liofilchem, Roseto degli 
Abruzzi, Italy), blaCTX-M PCR, XbaI-PFGE, S1-nuclease PFGE and PBRT as described 
above. 
 
Fitness cost of plasmid carriage 
The biological cost associated with carriage of the CTX-M-15-encoding 
plasmid in CTX-M-15-Kp in vitro was estimated in two ways: (i) by pairwise head-to-
head competitions between plasmid-free segregant isolates and their corresponding 
plasmid-carrying ancestor isolates in mixed culture competitions, and (ii) by 
comparing the growth rates of plasmid-free segregants and their corresponding 
plasmid-carrying populations in monocultures.  
For preconditioning, evolved CTX-M-15-Kp plamid-carrying acestor isolates 
and their corresponding plasmid-free segregant isolates (all recovered at the endpoint 
of the serial transfer experiment and frozen at -70˚C) were inoculated on LB plates, 
with cefotaxime 8 mg/L for plasmid-carrying isolates and without cefotaxime for 
segregant isolates, and cultured at 37˚C ON. Then, single colonies were picked and 
cultured in LB broth ON. The ON cultures were serially diluted 1:1000 and incubated 
for another 14 hours before fitness experiments were conducted. 
Pairwise head-to-head competition experiments were performed in triplicates 
and repeated three times as previously described (302, 303). Approximately 2.5x106 
cells of each competitor were transferred into 1 ml LB broth. The mixed cultures were 
incubated shaking at 37°C for 12 hours, allowing eight to nine generations per 
competition. Initial (N0) and final (N12) densities (cfu/mL) of each competitor were 
determined by selective and non-selective plating. Relative fitness (w) measurements 
were estimated as described (302, 303). Briefly, from the initial (N0) and final 
densities (N12) the population growth of each competitor, known as its Malthusian 
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parameter (m), was determined using the equation m=ln(N12/N0). The value w for each 
segregant isolate was estimated as a ratio of the Malthusian parameter of the plasmid-
free segregant (m1) to that of the corresponding plasmid-carrying ancestor isolate (m2) 
(302). 
Growth rates of plasmid-carrying ancestor isolates and their corresponding 
plasmid-free segregant isolates were determined during logarithmic growth using a 
VersaMax Microplate Reader (Molecular Devices, Sunnyvale, USA). Approximately 
2x105 cells of each population were inoculated into 200 ȝl LB broth and incubated 
shaking at 37°C in monocultures. Each isolate was assayed in three independent 
cultures, with three technical replicates per culture, in at least two independent 
experiments. Absorbance was recorded at 650 nm at regular intervals of five minutes. 
Growth rate calculations were based on OD650 values between 0.1 and 0.6, where 
growth was observed to be exponential using the program GrowthRates (304). Every 
growth rate calculation was also manually inspected. Relative growth rates were 
calculated by dividing the growth rate of plasmid-free segregant isolates by the growth 
rate of the corresponding plasmid-carrying ancestor isolate.  
 
3.7 Statistics 
Kaplan-Meier survival analysis was performed to calculate the median time of 
faecal CTX-M-15-Kp carriage in children and colonized HCs. For each child, the 
duration of CTX-M-15-Kp carriage was calculated as the average of the time from 
hospital discharge until the last CTX-M-15-Kp positive sample, and the time from 
discharge until the first CTX-M-15-Kp negative sample. For colonized HCs, the 
duration of carriage was calculated as the average of the time from the first CTX-M-
15-Kp positive sample until the last positive sample, and the time from the first 
positive sample until the first negative sample. In subjects without complete follow-up, 
the first missing sample was considered the first negative or last positive sample in 
children and HCs, respectively (The follow-up study).The logrank test was used to 
compare the carriage times between children and parents. For testing the effect of 
various variables (risk factors) on carriage times in children, univariate and 
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multivariate Cox regression analysis was performed. Variables with P<0.25 in the 
univariate analysis were included in the stepwise selection. Relations between 
different variables were evaluated in a multivariate Cox regression model. The 
assumption of proportional hazards between groups over time was investigated by log 
minus log plots. Hazard ratios (HR) are reported with 95% confidence intervals (CI). 
Comparison of proportions between groups was analysed by Mc Nemar’s test for 
related samples. P values< 0.05 were considered statistically significant. PASW 
version 18 (SPSS Inc, Chicago, IL, USA) was used for analysis (The follow-up study). 
Students t-tests were used for the pairwise comparison of the relative fitness and 
the relative growth rates between isolates. Relative growth rates and w values are 
reported with 95% CI. Generation times are reported with mean ± standard error (SE). 
P values <0.05 were considered statistically significant. t-tests were performed in 
Excel (The plasmid study).  
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4 Summary of results 
 
The main results of the three sub-studies included in this thesis are summarized 
in this section. Further details are given in the respective papers. 
 
4.1 The NICU outbreak 
As the outbreak was recognized, screening revealed that 22/24 (92%) infants 
hospitalized in the NICU were colonized by ESBL-Kp. Furthermore, screening of 501 
children during the outbreak investigations revealed that altogether 58 children were 
colonized during the NICU outbreak (Figure 7). Colonized children had their stay in 
the NICU (n=51) or in the maternity wards (n=7) between 27 November 2008 and 17 
April 2009. A probable index case was identified as a newborn child transferred to our 
NICU from another Norwegian NICU on 27 November. ESBL-Kp was recovered 
from several frozen breast milk samples from this child’s mother, collected both 
before and after the transfer (for details see Table 1 and Figure 1, Paper I). ESBL-Kp 
was detected in 33/502 environmental samples, mainly taken from sink drains. Thirty 
HCWs accepted rectal screening, but none were found colonized. The implementation 
of strict infection control precautions (e.g. enhanced hand hygiene) and cohorting of 
patients and nurses in two separate units were considered to be of significant 
importance for the rapid outbreak control. One child suffered a systemic infection 
caused by the outbreak strain (ESBL-Kp positive blood culture), but recovered after 
treatment with meropenem. No patients died of reasons associated to the outbreak. 
All ESBL-Kp isolates expressed resistance to extended-spectrum 
cephalosporins and aztreonam, as well as clavulanic acid synergy. Most isolates 
displayed co-resistance to trimethoprim-sulfamethoxazole and gentamicin. All isolates 
were susceptible to carbapenems and ciprofloxacin. Molecular analyses were 
performed on the first faecal isolate obtained from each of the 58 colonized children, 
the blood culture isolate from one child and the first breast milk isolate from the 
mother of the index case (n=60). The presence of blaCTX-M-15 was confirmed in all 
isolates. Fifty-eight isolates displayed indistinguishable PFGE-patterns, designated 
PFGE-type I. Faecal isolates from two infants showed unrelated PFGE-type II 
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patterns. Isolates of pulsotype II were, in contrast to isolates of pulsotype I, susceptible 
to gentamicin. Pulsotype I isolates (including the index breast milk isolate and the 
invasive isolate) were of ST17 and pulsotype II isolates were of ST485. Both strains 
were PCR-negative for all tested virulence determinants. 
 
4.2 The follow-up study 
All ESBLA-producing K. pneumoniae isolates recovered during follow-up 
expressed the typical CTX-M-15 phenotype and co-resistances. Molecular analysis 
was performed on a selection of faecal ESBL-Kp follow-up isolates (n=92) from 51 
children and 12 colonized HCs. BlaCTX-M-15 was confirmed in all isolates. Pulsotype I 
(ST17) was confirmed in follow-up samples from 49 children and 11 HCs, and 
pulsotype II (ST485) was confirmed in follow-up samples from two children and one 
corresponding HC.  
The median carriage time of CTX-M-15-Kp in 51 children, after discharge from 
hospital, was estimated to 12.5 months (inter-quartile range (IQR) 9.5-17.5) by 
Kaplan-Meier survival analysis (Figure 1, Paper II). The longest period of carriage 
observed was ~24 months. Stable antimicrobial susceptibility patterns and PFGE-
profiles from the first to the last CTX-M-15-Kp isolate in all children supported stable 
persistence of CTX-M-15-Kp during long-term intestinal carriage.  
Clinical data from 42 children hospitalized in the NICU during the outbreak 
were available for risk analysis. Risk factors for prolonged faecal carriage, assessed by 
multivariate Cox regression analysis, were delivery by caesarean section (HR=4.5, 
95%, CI 1.6-12.6, P=0.004) and treatment with antibiotics during hospitalization 
(HR=2.4, 95% CI 1.1-5.5, P=0.029) (for further details see Table 1, Paper II). 
Transmission of CTX-M-15-Kp was observed in 12/60 (20%) HCs (i.e. 8/28 
mothers, 3/25 fathers and 1/7 siblings) from 9/28 (32%) households. Median carriage 
time in 11 parents was 2.5 months (IQR 1.0-5.0) (P<0.001 compared to infants).  
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4.3 The plasmid study 
Plasmid typing and profiling of selected CTX-M-15-Kp ST17 isolates (the first 
and the last faecal isolate from four children colonized for 18-24 months, and the 
index breast milk isolate) revealed the presence of a ~180 kb IncFIIK CTX-M-15-
encoding plasmid in all nine isolates. In 8/9 isolates the presence of an additional ~70 
kb IncR plasmid was confirmed. The last isolate from one child (Kp848), was devoid 
of the ~70 kb IncR plasmid (Figure 1 and Table 1, Paper III).  
Sequencing of the CTX-M-15-encoding plasmid of the CTX-M-15-Kp ST17 
outbreak strain uncovered a 182 204 kb IncFIIK plasmid, named pKp848CTX 
(GenBank accession number LM994717). A conserved transfer region and several 
plasmid maintenance systems were encoded by pKp848CTX. Plasmid pKp848CTX 
carried a Tn3-like transposon, encoding the antibiotic resistance genes blaCTX-M-
15(linked to ISEcp1) and blaTEM-208. Furthermore, the aminoglycoside resistance gene 
aac(3)-IIa, multiple heavy metal (i.e. mercury, arsenic, copper and silver) and 
thermoresistance determinants were identified on pKp848CTX. The core regions of 
pKp848CTX, as well as the conserved heavy metal and thermoresistance encoding 
region, were highly similar to corresponding regions in pKPN3 (Gene bank accession 
number CP000648) and pUUH239.2 (CP002474) (Figure 2, Paper III). 
We have no evidence of pKp848CTX self-transfer from CTX-M-15-Kp ST17 
to other Enterobacteriacea during two years of intestinal colonization. In line with this 
finding, pKp848CTX could also not be transferred from its K. pneumoniae host strain 
(CTX-M-15-Kp ST17) to E. coli J53-2 or back to plasmid-free CTX-M-15-Kp ST17 
segregants by mating experiments in vitro. 
Stable S1-nuclease PFGE profiles from the first to the last CTX-M-15-Kp ST17 
isolates from four children (Figure 1, Paper III), indicated that pKp848CTX was 
maintained by its K. pneumoniae host strain during the entire intestinal colonization 
period of up to two years. By screening ESBL-negative follow-up samples from 35 
children, previously colonized by CTX-M-15-Kp ST17, we could not detect any 
isogenic ESBL-negative K. pneumoniae isolates (i.e. CTX-M-15-Kp ST17 isolates 
devoid of pKp848CTX, and thus the CTX-M-phenotype). Hence, we have no evidence 
of plasmid loss in vivo. In the serial passage experiment, however, we uncovered an 
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endpoint segregant frequency after ~430 generations without antibiotic selection 
ranging between 0.0% and 17.5% in 16 evolved CTX-M-15-Kp ST17 populations 
(Table 2, Paper III). 
The biological cost of pKp848CTX carriage in CTX-M-15-Kp ST17 was 
studied in vitro. Plasmid-free segregant isolates were competed against their evolved 
corresponding plasmid-carrying ancestor isolates in mixed culture competitions, but no 
significant fitness cost associated with pKp848CTX carriage could be identified by 
this approach. However, a statistical significant reduction of fitness was seen for one 
segregant isolate (Kp2180) suggesting a subtle benefit of plasmid carriage (Table 2, 
Paper III). Growth rates of plasmid-free segregant isolates and their corresponding 
evolved plasmid-carrying ancestor isolates were measured in monocultures and 
compared. Generation times of the CTX-M-15-Kp ST17 isolates, with and without 
plasmid pKp848CTX, varied between 30.24 and 33.14 minutes (mean 31.17 ±0.658). 
Two plasmid-free segregant isolates (Kp2158 and Kp848) displayed increased growth 
rates indicating a significant biological cost of plasmid carriage (Table 2, Paper III). 
Moreover, one segregant (Kp734) displayed a statistically significant reduced growth 
rate suggesting a small benefit of plasmid carriage after two years of colonization. The 
results from the mixed culture competition experiments and the growth rate 
comparisons were not consistent and should be interpreted with caution. Also no 
difference in fitness was found between the first and the last isolate of individual 
children (all P>0.05, t-tests). 
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5 Discussion 
5.1 Methodological considerations 
 In this section the choice of methods, as well as their strengths and limitations, 
will be discussed. 
 
Study design and study population 
The first sub-study, describing the NICU outbreak, is a retrospective descriptive 
study. Retrospective studies will always have limitations as one cannot go back in time 
and implement additional measures or collect missing samples etc. In our setting, the 
study population was given in advance. Thorough investigations were made to disclose 
the extent and the source of this outbreak, which strengthens this study compared to 
other outbreak reports, where the source often remained unknown (247). 
The follow-up study is a prospective cohort study. The design of this study was 
also limited by some factors, which could not be influenced. The study population (i.e. 
the number of colonized children during the outbreak and their respective family 
members) was already set as we planned the study. The first follow-up samples were 
intended to be obtained within a month after hospital discharge. Some infants were 
already discharged before we were aware of the outbreak. Hence, their first follow-up 
samples were obtained 3-5 months after discharge. As all these infants, except one, 
were still colonized when they delivered their first follow-up sample, this did not 
influence our overall results (e.g. median CTX-M-15-Kp-carriage time). Due to the 
delayed follow-up in some families, we might have missed transient colonization in 
HCs. Furthermore, we missed information otherwise obtained by the questionnaires in 
some of the children (e.g. breast feeding, infections or antibiotic treatment during the 
first months after discharge). Altogether, the information obtained by the 
questionnaires was incomplete and of poor quality, and was therefore not included in 
the risk analysis. Initially, follow-up was planned for one year after hospital discharge. 
However, the study period was extended from one to three years, which allowed more 
infants to reach the endpoint of the study (i.e. clearance of CTX-M-15-Kp). The 
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longest carriage time observed in this study was ~24 months. Thus, all children, who 
completed follow-up, were followed until CTX-M-15-Kp clearance. 
The unique collection of isolates recovered during the NICU outbreak and the 
follow-up study, gave us the opportunity to perform the plasmid study. The strength of 
the plasmid study is the design combining modern sequencing technology with both in 
vivo and in vitro studies of the CTX-M-15-encoding plasmid and its K. pneumoniae 
host strain.  
 
ESBL-screening  
During the early outbreak investigations, children were screened by swabbing 
the conjunctiva, nasopharynx and the rectal area (or faeces). However, only 8% (2/25) 
and 12% (3/25) of children with ESBL-positive rectal/faecal samples had additional 
ESBL-positive conjunctival or nasopharyngeal samples, respectively. Bagattini et al. 
reported 47.4% positivity by rectal swabbing, followed by 35.5% and 26.4% positivity 
in throat and nose cultures, respectively, during a NICU outbreak caused by ESBL-
producing K. pneumoniae (252). We did not obtain oropharyngeal swabs, which might 
have been of higher value than nasopharyngeal swabs. However, we concluded that 
rectal/faecal samples were superior to conjunctival and nasopharyngeal samples for 
ESBL-E screening in our setting, and continued to screen only rectal/faecal samples 
throughout the outbreak and during the follow-up study. Perirectal swabs are 
commonly used and considered adequate for ESBL-E screening both in hospitalized 
and healthy persons (246, 273), supporting our choice. 
Children admitted to the NICU were repeatedly screened during the outbreak 
(every 2-3 days). Screening samples from newborn children were ESBL-negative 
during their first days of life, but turned ESBL-positive on the second or third day in 
most children before strict cohorting was established (unpublished data). This 
observation emphasizes the importance of repeated screening in a NICU outbreak 
situation, where the risk of cross-transmission between patients is considered to be 
high (247). Children admitted to the maternity wards, or already discharged from the 
NICU or maternity wards, were only screened once. Also HCWs provided only one 
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screening sample. Hence, transient or low levels of colonization in these groups may 
have remained undetected. 
In the follow-up study, we defined elimination of CTX-M-15-Kp in colonized 
children as three or more consecutive negative faecal samples, as also suggested by 
Alsterlund et al. (232) and Kola et al. (267). In contrast, a recent Swedish follow-up 
study reported duration of carriage until the first negative sample (235). In our study, 
29/41 children, who completed follow-up had four or more negative samples. None of 
the 41 children had a CTX-M-15-Kp positive sample after three or more consecutive 
negative samples. Two children, however, had one positive sample after two negative 
samples, and four children had one positive sample after one single negative sample. 
Hence, the overall results of the follow-up study support the chosen definition of CTX-
M-15-Kp elimination. Both children and HCs were screened every 1-3 months during 
the follow-up study. Due to the chosen screening schedule, is possible that we missed 
transient or short-term colonization (< 3 months) in some HCs. 
 
Statistical methods (The follow-up study) 
Kaplan-Meier survival analysis was performed to determine the duration of 
CTX-M-15-Kp carriage (i.e. the time until CTX-M-15-Kp clearance) in infants and 
colonized HCs. The power of a survival analysis is not related to the total sample size, 
but to the number of subjects who reach the event of interest or the defined endpoint 
(305). In our study, CTX-M-15-Kp clearance ( 3 consecutive negative samples) was 
defined as the endpoint of the survival analysis. The majority of the infants (41/51) 
reached the endpoint as we extended the study period from one to three years. The 
remaining 10 infants stopped providing screening samples before reaching the 
endpoint of the study (< 3 consecutive negative samples). However, their follow-up 
data were included in the survival analysis as censored survival times. In most studies, 
where survival analysis is applied, the endpoint (e.g. death or recurrence of a disease) 
is well defined, whereas the start (e.g. onset of a disease) may be less well defined. In 
our study all infants were colonized by CTX-M-15-Kp during a four month period and 
we know the exact date of hospital discharge, which was defined as the start point in 
this study. We consider Kaplan-Meier survival analysis to be the most appropriate 
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statistical method for the estimation of ESBL-carriage times in a group of subjects like 
in our setting. This approach was also chosen by Birgand et al. (236). In contrast, most 
other carriage studies report proportions of subjects still being carriers at different time 
points e.g. three, six, nine and 12 months after ESBL-infection or colonization (232, 
233, 235).  
The logrank test is the most common used method for comparing independent 
groups of survival times. Thus, we chose this test for comparing carriage times 
between children and colonized parents. The logrank test should, however, not be used 
when exploring the effects of multiple variables on survival (305). Thus, we chose to 
perform Cox regression analysis for exploring risk factors for prolonged ESBL-
carriage in children colonized during a NICU outbreak. As carriers were compared to 
carriers, we did not have the possibility to include controls for the risk analysis in this 
study. It is generally complicated to perform power analysis in advance of regression 
analysis. In our setting, where knowledge lacked concerning the variables of interest 
(i.e. expected duration of carriage and possible risk factor for long-term carriage), we 
did not have the possibility to perform any meaningful power analysis. Furthermore, 
the number of available subjects was set, and we would not have had the option to 
include more subjects in order to increase the power of the risk analysis. Forty-two 
children and six potential risk factors were included in the Cox regression analysis 
(Table 1, Paper II). As listed in the table, the number of children in the groups to be 
compared varied between the variables. Due to low numbers of subjects in some of the 
groups, type 2 errors may have occurred. Consequently, all negative results may not be 
true negative, and should be interpreted with care.  
 
Bacterial strain typing  
XbaI-PFGE was chosen for bacterial strain typing in this study. MLST was only 
performed on selected isolates in order to detect possible epidemiological links 
between the outbreak strain from our NICU and other outbreak strains. PFGE has high 
discriminatory power and is generally considered to be the gold standard for typing of 
Enterobacteriacea isolates in a local outbreak situation. PFGE, however, is time 
consuming and a more rapid typing method would have been useful, especially during 
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the outbreak. Currently, commercial PCR-based typing methods are increasingly used 
for more rapid strain typing (278). Their discriminatory power compared to PFGE is 
debated (279). During recent years, WGS has become cheaper and more available. 
WGS has high discriminatory power and may soon become an important tool for strain 
typing, also in outbreak situations (280, 281). However, during the outbreak in 2008-
09, WGS was not available in our hospital. 
 
Plasmid typing  
Plasmid typing is challenging due to the diversity and genetic plasticity of 
plasmids. In this study, we chose to combine PBRT, S1-PFGE and subsequent 
Southern blot-hybridization to characterize and compare the plasmid content of the 
selected isolates. PBRT is easy and fast to perform and has the advantage that results 
(i.e. Inc types) may be compared between laboratories, and thus provides valuable 
epidemiological information. S1-PFGE is more time-consuming to perform, but gives 
information about the number and sizes of plasmids carried by bacterial isolates. 
Through Southern blot-hybridization with relevant probes, ESBL-plasmids and their 
Inc types may be identified. As for bacterial strain typing, WGS may have the 
potential to replace the above mentioned methods for plasmid identification and typing 
in the near future (282, 283). 
 
Plasmid sequencing 
We obtained the complete circular DNA sequence of pKp848CTX using the 
454-technology of Roche on a shotgun library, and by subsequent sequence-based gap 
bridging. By this approach some hours of wet lab work are required to gain a circular 
plasmid sequence. However, sequencing technology is evolving fast and it is 
becoming easier and cheaper to obtain a de novo plasmid sequence or even the 
sequence of a complete bacterial genome, as the length of reads is becoming longer 
and consequently the number of contigs and gaps fewer. The GS FLX+ system of 
Roche now provides read lengths up to 1 kb and the PacBio RSII system provides 
reads up to 10 kb. A number of full sequenced plasmids have been published during 
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recent years. However, even if modern sequencing technology may open new doors 
into biology, there will always be a gap between geno- and phenotype. Thus, the 
importance of combining WGS with studies of phenotypes must be emphasized, and is 
one of the strengths of this study. 
 
Plasmid transfer, stability and fitness cost experiments 
 Although we could not detect transfer of pKp848CTX from CTX-M-15-Kp 
ST17 to E. coli J53-2 or to clonally identical plasmid-free CTX-M-15-Kp segregants 
in vitro, we cannot principally exclude that pKp848CTX may have been transferred 
below our limits of detection (1x10-9/donor and 3.3x10-9/donor, respectively). Also in 
vivo, it is possible that transconjugants remained undetected. Furthermore, the 
possibility of in vitro self-transfer of pKp848CTX after transformation into other hosts 
cannot be excluded, as this was not in the scope of this study.  
Our in vivo results suggested that pKp848CTX was stably maintained by CTX-
M-15-Kp ST17 during intestinal colonization. To test the stability of pKp848CTX in 
its K. pneumoniae host in vitro, we performed a serial passage experiment for ~ two 
months (achieving ~ 430 generations). We assumed the plasmid to be stably 
maintained by its host also in vitro, therefore we only screened for segregants at the 
endpoint of the experiment. Considering the high variability in the endpoint segregant 
frequencies between the evolved populations, it would have been interesting to have 
data on plasmid loss rates at several points during the serial transfer experiment. 
Although, such data would probably not have influenced our conclusion that 
segregants emerge stochastically and escape bottlenecks at different time points 
resulting in variable endpoint segregant frequencies as discussed in paper III. 
 To assess the biological cost of pKp848CTX carriage in CTX-M-15-Kp ST17, 
we first performed 24-hour mixed culture competition experiments. Due to the rapid 
growth of both the plasmid-carrying and the plasmid-free segregant isolates, we chose 
to modify the experimental setup and performed 12-hour competitions, which were 
found to be more convenient for this strain. As we could not uncover any significant 
fitness cost associated with plasmid carriage by this approach, we also compared the 
growth rates of the plasmid-free segregant isolates and their corresponding plasmid-
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carrying mother isolates to test whether we could capture fitness costs below the 
resolution of mixed culture competitions. However, the growth rate results should be 
interpreted with caution since they merely reflect a short time-span of logarithmic 
growth, whereas the mixed culture competition experiments include the complete 
growth cycle of the two competitors.   
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5.2 Discussion of the results 
The main results of the three sub-studies are discussed in the respective papers. 
In this section, some results will be discussed more in detail and linked together when 
relevant. 
 
5.2.1 The NICU outbreak 
The extent of the outbreak 
By screening hospitalized children and children already discharged from the 
NICU or maternity wards when the outbreak was recognized, we identified 58 children 
colonized by CTX-M-15-Kp. However, the number of colonized children may be 
underestimated. Some children already discharged from the NICU before we became 
aware of the outbreak, were missed for screening. Furthermore, discharged children 
only delivered one single screening sample and transient carriage may have remained 
undetected in some of these children. As discussed in section 5.1, the results of the 
follow-up study indicate that three consecutive negative screening samples would be 
appropriate in order to rule out ESBL-colonization.  
 
Infection control measures 
The implementation of strict infection control measurements, e.g. enhanced 
hand hygiene, intensified cleaning, strict barriers between patients and cohort nursing 
within the NICU, was not sufficient to interrupt the outbreak and prevent spread of 
ESBL-Kp to more children. Consequently, the original NICU was closed for new 
admittances, and a second preliminary NICU was established to care for new 
admittances. In our setting, cohorting of colonized and non-colonized patients and two 
groups of staff into two separate units was considered to be of great importance for the 
rapid control of the outbreak. The infection control measurements implemented to 
contain the outbreak in our NICU are in line with those implemented in most other 
reported NICU outbreaks (247). Laurent et al. reported that cohorting was the most 
important measure in controlling an outbreak caused by ESBL-producing K. 
84 
 
pneumoniae in an adult ICU, where routine infection control measures failed to 
interrupt the outbreak (306). In line with this finding, Tacconelli et al. recently 
recommended cohorting of both patients and staff to control MDR K. pneumoniae 
outbreaks among adult patients (246). In our opinion, this recommendation is also 
relevant in the NICU setting. 
Transient carriage of ESBL-producing K. pneumoniae on HCWs hands has 
been found to be a common cause of transmission, especially between infants during 
NICU outbreaks (254, 263, 264). Although we did not screen HCWs hands, we 
suggest that patient-to-patient transmission via HCWs hands may have been an 
important mechanism for the efficient spread of ESBL-Kp between infants during the 
outbreak in our NICU. In this study, HCWs (37.5%) were only screened by rectal 
swabbing. In contrast to other studies, none were found colonized (247, 307). The 
significance of faecal ESBL-colonization in HCWs, if detected, may be debated; 
colonization in HCWs may as well be a result of intensive patient care as HCWs being 
the source of the outbreak, and as long as HCWs practice good hand hygiene their 
ESBL-carrier state should not cause transmission to patients. 
Extensive screening of patients and hospital environment was performed during 
the outbreak to identify the source and to gain control. ESBL-Kp was detected in 6.5% 
of the environmental screening samples, but most of these were taken from sink drains 
and were considered to be contaminated by patients, or by the hands of HCWs or 
parents, rather than being the source of the outbreak. After the outbreak, the NICU was 
decontaminated using a hydrogen peroxide dry aerosol decontamination system (308) 
including silver ions (O. B. Natås, personal communication). Patients admitted to the 
NICU after the decontamination procedure were screened weekly for three months (18 
April to 3 July), and no new cases were identified. Also environmental samples taken 
after the decontamination procedure, were all ESBL-negative indicating successful 
eradication of the outbreak strain from the hospital environment. 
 
The source of the outbreak 
The patient population is considered the most important reservoir in nosocomial 
ESBL-E outbreaks (95). In this study, a probable index case was identified as a child 
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transferred to our NICU from another hospital on 27 November 2008. CTX-M-15-Kp 
ST17 was isolated from frozen breast milk samples from this child’s mother, collected 
before and after transfer. None of 32 children discharged from the NICU between 1 
November and 27 November were found colonized, which strengthens the hypothesis 
that this child was the index case. In contrast, the source remained undetected in 
48.6% of reported NICU outbreaks (247).  
In paper I, we suggest that mother-to-neonate transmission due to contaminated 
breast milk was the most probable mechanism of ESBL-colonization in the index case. 
Transmission of group B streptococci and Enterobacteriaceae from mothers to 
neonates via breast milk has been reported previously (309, 310). However, other 
transmission routes have to be considered. The faecal and vaginal carrier state of the 
mother at the time she gave birth is unknown. Vertical transmission during delivery 
has been reported in cases where ESBL-producing E. coli was isolated from urinary, 
genital or faecal samples of mothers (311-314). The index case in our study was born 
by caesarean section, which reduces the risk for transmission during delivery. Children 
born by caesarean section are rather colonized by bacteria present in the hospital 
environment than by the maternal vaginal or faecal flora (239). Hence, a further 
possibility is that the index case was colonized by a strain present in the NICU 
environment in the hospital where it was born. In this hospital ESBL-screening was 
performed on all clinical Enterobacteriaceae isolates from NICU patients as they 
became aware of the outbreak in our hospital, but CTX-M-15-Kp was not detected (P. 
E. Akselsen, personal communication). As screening was implemented three months 
after transfer of the index case, we still cannot rule out that CTX-M-15-Kp was 
silently present in the other NICU before the index case was transferred. 
The mother of the index case had no typical risk factors for ESBL-colonization, 
e.g. origin from or recent travel to endemic areas or history of broad-spectrum 
antibiotic use. And it is still unknown if the mother was in fact colonized before her 
child, and if yes, we don’t know if she brought the CTX-M-15-Kp strain from the 
community to the hospital, or if she was colonized in the hospital where she gave 
birth. CTX-M-15-Kp was detected in several breast milk samples from the mother of 
the index case, and asymptomatic excretion and subsequent colonization of her child 
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via breast milk is possible. On the other hand, neonate-to-mother transmission can also 
not be excluded. The mother’s breast, and subsequently the expressed breast milk, may 
have been contaminated by her infant, if the infant was colonized first. The infant 
received expressed breast milk from its mother through a nasogastric tube, but was 
also laid to its mother’s breast as often as possible. 
In areas with high ESBL-E carriage rates in the community, the influx of 
ESBL-E from the community to hospitals is of concern, as emphasized by Ben-Ami et 
al. (315). Denkel et al. recently concluded that the mother is the most important risk 
factor (OR 7.4, 95% CI 2.1-26.7, P = 0.002) for ESBL-E colonization of very low 
birth weight infants (314). In a Spanish study, 9.6% (39/406) of mothers giving birth 
were colonized by ESBL-E. Transmission of ESBL-E was found in seven mother-
neonate pairs (18%) (313). In a recent study in the South West Region of Norway, we 
found that 2.9% (26/896) of pregnant women were colonized by ESBL-E before 
giving birth, and mother-to-neonate ESBL-E transmission was confirmed by PFGE in 
five mother-neonate pairs (19%) (S. Rettedal et al., unpublished data). The results of 
the above listed studies indicate that screening of mothers might be of importance in 
order to reduce the risk of ESBL-E import to NICUs, at least in settings with high 
carriage rates in the community. 
 
Properties of the outbreak strain 
Molecular investigations revealed that two CTX-M-15-Kp strains were 
coexisting in the NICU during the beginning of the outbreak: 56 children were found 
colonized by the CTX-M-15-Kp ST17 strain and two children by an unrelated ST485 
strain. In paper I, we suggest plasmid-mediated transfer of blaCTX-M-15 between the two 
K. pneumoniae strains involved in the outbreak. However, subsequent plasmid 
profiling and typing did not confirm this hypothesis. BlaCTX-M-15 was encoded by a 
~180 kb IncFIIK plasmid in the ST17 outbreak strain (Paper III), and by a ~75 kb IncI1 
plasmid in the ST485 strain (supplementary unpublished data). Thus, two unrelated K. 
pneumoniae strains, carrying unrelated CTX-M-15-encoding plasmids, seem to have 
coexisted in the NICU during the first weeks of the outbreak.  
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The CTX-M-15-Kp ST17 outbreak strain is closely related to the CTX-M-15-
producing K. pneumoniae ST16 strain, which caused a large hospital outbreak in 
Uppsala University Hospital in 2005 (21, 142). ST16 and ST17 are single locus 
variants belonging to the clonal complex (CC) 16. CTX-M-15-producing K. 
pneumoniae ST16 has also been detected in the Copenhagen area (278), indicating that 
strains belonging to CC16 are common in Scandinavia.  
No patients died of reasons associated with the NICU outbreak in our hospital, 
and only one patient suffered a systemic infection caused by CTX-M-15-Kp. Due to 
the low infection-colonization rate (1:57) during the outbreak, it seems plausible to 
assume that CTX-M-15-Kp ST17 had low virulence properties. In line with this 
assumption, both the ST17 and the ST485 strain lacked all the virulence determinants 
we screened for. The zero mortality during the NICU outbreak in our hospital contrasts 
to mortality rates reported from other NICU outbreaks. Gastmeier et al. reported an 
average mortality during NICU outbreaks associated with Klebsiella spp. of 11.8% 
(247).  
The ST17 outbreak strain seems to have outdone the ST485 strain during the 
first weeks of the outbreak, which indicates higher fitness of the ST17 strain under the 
given conditions. Empirical antibiotic treatment of systemic infection in the NICU, 
before and during the first months of the outbreak (until we became aware of the 
outbreak), was ampicillin and gentamicin in combination. The ST17 strain, which 
spread efficiently in the NICU environment, was co-resistant to gentamicin, whereas 
the ST485 strain lacked this resistance trait. Thus, the gentamicin resistant phenotype, 
in addition to the ESBL-phenotype, may have favored the clonal dissemination of the 
ST17 strain.  
 
Characteristics of the outbreak plasmid 
The DNA sequence of the CTX-M-15-encoding IncFIIK plasmid of CTX-M-15-
Kp ST17 (pKp848CTX), uncovered a pKPN3-like backbone similar to that in 
pUUH239.2, the CTX-M-15-encoding plasmid in the Uppsala K. pneumoniae ST16 
outbreak strain (21). Interestingly, these two plasmids from related K. pneumoniae 
strains seem to have a common ancestor and several additional common traits, such as 
88 
 
heavy metal and thermoresistance (Figure 2, Paper III). A plasmid-encoded 
thermoresistance gene cluster similar to that in pKp848CTX and pUUH239.2 was 
recently described in Danish K. pneumoniae isolates (316). A thermotolerant 
phenotype, along with heavy metal resistance, has been proposed to increase bacterial 
survival and persistence in the hospital environment and on medical devices (143, 
317). Copper, silver and thermoresistance have been described to have impact on the 
effectiveness of sterilization and decontamination methods used to decontaminate the 
hospital environment and invasive equipment (143, 316, 318). Thus, it is possible that 
a plasmid-mediated heavy metal and thermoresistant phenotype, if significantly 
expressed, may have contributed to the survival and spread of CTX-M-15-Kp ST17 in 
the NICU environment during the outbreak. The CTX-M-15-encoding IncI1 plasmid 
of the ST485 strain has not been sequenced. Hence, it is unknown if this plasmid 
encodes similar traits.  
 
5.2.2 The follow-up study 
Duration of ESBL-carriage 
This is the first study to report the duration of faecal ESBL-carriage in children 
colonized during a NICU outbreak. The median carriage length of CTX-M-15-Kp was 
12.5 months after discharge from hospital, and some children were carriers for up to 
two years, which is longer than most of the carriage times observed in adults after 
recent ICU hospitalization or ESBL-infection (236, 237). However, Titelman et al. 
found that 43% of adult patients were still colonized by ESBL-E 12 months after 
infection (235), and Alsterlund et al. reported that 13% carried ESBL-producing E. 
coli for up to 59 months after a nosocomial outbreak (232). These reports indicate that 
long-term ESBL-E carriage may also be expected in adults, especially after ESBL-E 
infection or nosocomial outbreaks. Knowledge about expected carriage times is of 
importance for infection control purposes during hospitalization and in the case of re-
admittance (246). Due to our results, screening of children colonized by ESBL-Kp 
during a NICU outbreak may be considered for 1-2 years after discharge, if re-
admitted to hospital. Of notice, we only studied the carriage times of one K. 
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pneumoniae strain carrying an ESBL-plasmid, which was not self-transferable. Thus, 
the results might have been different if the carriage times of diverse strains were 
studied.  Altogether, further studies are needed for the estimation of expected carriage 
times of diverse ESBL-E strains in different populations. 
 
Risk factors for prolonged ESBL-carriage 
Factors, such as low gestational age, low birth weight, the use of invasive 
devices, antibiotic treatment and duration of hospital stay, have been associated 
increased risk of ESBL-E colonization in infants hospitalized in NICUs (253, 258-
260). We investigated risk factors for becoming colonized by CTX-M-15-Kp during 
the outbreak in our NICU. In line with previous studies, we found that prematurity 
(gestational age < 37 weeks) and treatment with antibiotics (i.e. ampicillin and 
gentamicin in combination) were independent risk factors for becoming colonized 
(319).  
Risk factors for prolonged duration of colonization in children colonized during 
a NICU outbreak have until present not been investigated, but it seems plausible that 
some of the factors mentioned above could also influence the duration of carriage. 
Thus, we examined the impact of gender, gestational age, treatment with antibiotics 
(ampicillin and gentamicin in combination) during NICU hospitalization, mode of 
delivery and feeding regime on the duration of CTX-M-15-Kp colonization. Treatment 
with antibiotics and delivery by caesarean section were found to be significant risk 
factors for prolonged CTX-M-15-Kp carriage.  
Mode of delivery is the first factor which may affect the early intestinal 
colonization (239). Several studies report lower counts of Bacteroides spp. and 
bifidobacteria in infants delivered by caesarean section compared to vaginally 
delivered infants from three days up to six months of age (320-322). Hence, it is 
biological plausible that children born by caesarean section and subsequently 
hospitalized in a NICU may be at risk for long-term faecal carriage of a nosocomial K. 
pneumoniae strain if colonized.  
Early antibiotic treatment in infants has also been associated with delayed 
intestinal colonization of beneficial bacteria (241, 243, 323, 324). In a recent study, the 
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gut microbiota of nine infants, who received antibiotic treatment with ampicillin and 
gentamicin within 48 hours after birth was compared to that of nine controls, using 
high-throughput sequencing and quantitative PCR. The authors showed that the gut 
microbiota of infants that underwent antibiotic treatment had significantly higher 
proportions of Proteobacteria, and significantly lower proportions of Actinobacteria, 
Bifidobacterium and Lactobacillus, compared to controls at four weeks. By eight 
weeks, the levels of Proteobacteria were still high in antibiotic treated infants, whereas 
the levels of Actinobacteria, Bifidobacterium and Lactobacillus had recovered (325). 
These findings emphasize, that antibiotic treatment during the first days of life may 
provide a favourable niche for intestinal colonization by Enterobacteriaceae, and 
furthermore, promote long-term carriage of Enterobacteriaceae, including those 
producing ESBL (325).  
 
Intra-household ESBL-transmission 
We documented transmission of ESBL-Kp to 20% of HCs, which is in line with 
transmission rates reported by others (202, 215, 218, 234). Our data suggest that 
children colonized by ESBL-E during hospitalization may constitute a source for 
ESBL-E spread within their households. In contrast to the studies referred to above, 
the index cases were young children (< three years of age) in this study, and the 
parents were aware of the carrier state of their child and were continuously informed 
about the screening results. Furthermore, the parents were educated to practice good 
hand hygiene when changing diapers etc. to prevent spread. These factors may have 
reduced the transmission rate, and it is possible that young children represent a higher 
risk for intra-household transmission of ESBL-E than demonstrated by this study.  
The median carriage length of CTX-M-15-Kp in colonized parents was 
considerably shorter than in the children in this study. This observation may indicate 
that the risk of long-term carriage of an ESBL-Kp strain is higher in children colonized 
in the neonatal period than in healthy adults, which would be biological plausible. 
However, our carriage data in adults are limited, and further studies are needed to 
investigate the duration of faecal carriage in healthy children and adults. 
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5.2.3 The plasmid study  
We determined the complete DNA sequence of the CTX-M-15-encoding 
IncFIIK plasmid (pKp848CTX) from the CTX-M-15-Kp ST17 NICU outbreak strain, 
and investigated the plasmids dynamics and persistence in its K. pneumoniae host 
during two years of intestinal colonization in four children. 
 
Plasmid pKp848CTX 
The backbone of pKp848CTX revealed high sequence similarities to pKPN3 
and other pKPN3-like plasmids (Figure 2, Paper III), including the Swedish 
pUUH239.2 (21), the Czech pKPN_CZ (143), the American pBK32179 (326), the 
Italian pKPN-IT (327), and the Korean pKP09085, pKP02022 and pKP007 (328). The 
worldwide dissemination of pKPN3-like plasmids into diverse K. pneumoniae strains 
indicates high stability and robustness of this backbone. Of notice, plasmid 
pKp848CTX seem to have evolved by the transposition of a Tn3-like transposon into a 
pKPN3-like backbone, whereas the related pUUH239.2 evolved by IS26-mediated 
integration of a completely different antibiotic resistance cassette into a similar 
backbone (21).  
The Tn3-like transposon of pKp848CTX, encoding blaCTX-M-15 and blaTEM-208, is 
similar to transposon structures described in pEK204 and pEK516, isolated from E. 
coli ST131 strains in the UK (329). Furthermore, pKp848CTX carries the 
aminoglycoside resistance determinant aac(3)-II and a mercury resistance gene cluster. 
Similar mercury resistance gene clusters are present in pKPN4 and in the KPC-3 
encoding pKPN4-like plasmids pKpQIL and pKpQIL-IT (141, 327). Conserved heavy 
metal and thermoresistance regions, similar to that in pKp848CTX, are present in 
several other pKPN3-like plasmids, such as pUUH239.2 and pKPN_CZ, (21, 143, 
327, 328). Both pUUH239.2 and pKPN_CZ were isolated from K. pneumoniae strains 
associated with nosocomial outbreaks, suggesting that plasmid-mediated heavy metal 
and thermoresistance traits may favor the dissemination of the host in the hospital 
environment (as discussed in 5.1). 
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Plasmid transfer 
Although pKp848CTX encodes a conserved transfer region, we have no data 
confirming in vivo or in vitro transfer of pKp848CTX from CTX-M-15-Kp ST17 to E. 
coli or other Enterobacteriaceae strains. Also the attempt to conjugate pKp848CTX 
back to plasmid-free CTX-M-15-Kp ST17 segregant isolates failed. Plasmids similar 
to pKp848CTX could not be detected in any other intestinal strains during up to two 
years of follow-up of 49 children. Also in colonized HCs, we found no evidence of 
plasmid transfer in vivo (unpublished data). Thus, in contrast to pUHH239.2 and 
pKPN_CZ (20, 21, 143), pKp848CTX does not seem to be self-transferable, at least 
not when hosted by CTX-M-15-Kp ST17.  
In line with the findings from Rogers et al. (330), our results suggest that CTX-
M-15-Kp ST17 carriage was dependent on the persistence of a strain-plasmid 
combination rather than the persistence of the plasmid alone after HGT to other 
bacteria, which may have limited the persistence of pKp848CTX in the intestine of 
children during long-term carriage. The plasmid not being capable of self-transfer 
when hosted by CTX-M-15-Kp ST17 may also have limited the outbreak to clonal 
spread. Hence, the extent and outcome of the outbreak could have been of another 
dimension if the plasmid was transferrable by HGT. 
 
Plasmid stability and fitness cost 
The dynamics between an ESBL-producing host strain and its ESBL-encoding 
plasmid have to the best of our knowledge not yet been studied during human 
colonization. We studied the CTX-M-15-encoding plasmid of CTX-M-15-Kp ST17 
with regard to persistence, stability and fitness cost in relation to its host both in vivo 
and in vitro. 
Plasmid pKp848CTX was found to be maintained by its K. pneumoniae host 
strain throughout the intestinal colonization period of up to two years in four children 
(who did not receive antibiotics during follow-up). Furthermore, we found no evidence 
of plasmid loss during carriage by screening ESBL-negative follow-up samples of 
these children for plasmid-free isogenic K. pneumoniae isolates. Also ESBL-positive 
samples were screened for ESBL-negative isogenic K. pneumoniae isolates, but again 
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we could not detect any segregants in vivo (unpublished data). These results lead to the 
assumption that plasmid pKp848CTX is well adapted to CTX-M-15-Kp ST17, confers 
negligible fitness cost to its host in vivo, and that the elimination of CTX-M-15-Kp in 
colonized children was due to outnumbering of the strain per se rather than plasmid 
loss. 
To assess the stability of pKp848CTX carriage in CTX-M-15-Kp ST17 in vitro, 
we performed a serial transfer experiment. Surprisingly, and in contrast to the results 
from Sandegren et al., who reported no segregational loss of the similar IncFIIK 
plasmid pUUH239.2 over 1250 generations (21), plasmid-free segregants were easily 
recovered with frequencies ranging between 0.0% and 17.5% after ~430 generations in 
serial transfer cultures without antibiotic selection. This highly variable pattern may be 
accountable to our 10-fold decreased bottleneck in the serial transfer regime, compared 
to the study of Sandegren et al., which reduced the probability for stochastic loss of 
initially rare segregants from populations.  
Interestingly, pKp848CTX encodes several post-segregational killing systems 
(parB, sopAB and relE) (331-333), which are likely to prevent segregant formation 
through improper plasmid partitioning upon cell division. Considering the detected 
segregant rates of up to 17.5% in one of the evolved populations, one may question 
how well-tuned or functional these systems really are. However, also in the presence 
of active partitioning and post-segreagational killing systems, segregants may arise at 
low frequencies (334). In line with the assumption of de Gelder et al. (334), the 
variability in the segregant frequencies observed at the endpoint of the serial transfer 
in this study is likely to be representative for an evolving population, in which 
segregants emerge stochastically and escape bottlenecks at different time points, and 
thus rise in frequency at different time points resulting in different endpoint 
frequencies. Therefore, we hypothesize that relatively frequent segregational loss 
affects plasmid stability in CTX-M-15-Kp ST17 in an experimental non-selective 
environment to a greater extent than plasmid-conferred fitness costs. This hypothesis is 
supported by the results of our fitness cost experiments, where only small fitness costs, 
if any, could be uncovered for pKp848CTX carriage in CTX-M-15-Kp ST17.  
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Finally, we found no differences when comparing fitness cost of plasmid 
carriage in the first and the last isolates of the four children, supporting the hypothesis 
that plasmid pKp848CTX was readily well adapted to CTX-M-15-Kp ST17, even 
before it entered the NICU, and before the children were colonized. 
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6 Conclusions  
 
Considering the aims of this study, the following conclusions could be drawn 
based on the results of the three sub-studies included in this thesis: 
 
¾ The multidrug resistant CTX-M-15-producing K. pneumoniae (CTX-M-15-Kp) 
ST17 strain spread efficiently among infants during the NICU outbreak. 
¾ Despite the high colonization rate among infants, the rate of clinical infection 
was low, and no death was associated with the outbreak, indicating low 
virulence properties of the outbreak strain.  
¾ In total 56/58 children were colonized by CTX-M-15-Kp ST17, whereas two 
were colonized by an unrelated ST485 strain. The ST17 outbreak strain was in 
contrast to the ST485 strain co-resistant to gentamicin, which may have given 
this strain a selective advantage in the NICU environment. 
¾ One child was identified as the probable index case, and vertical mother-to-
neonate transmission of CTX-M-15-Kp may have been the mechanism for 
colonization of this child.  
¾ Patient screening and implementation of rigorous infection control measures, 
such as enforced hand hygiene and strict cohorting of patients and staff, were of 
great importance for the rapid control of the outbreak.  
 
¾ Children may become faecal carriers of ESBL-producing K. pneumoniae for up 
to two years after colonization during a NICU outbreak.  
¾ Delivery by caesarean section and antibiotic treatment during hospitalization 
may be risk factors for prolonged ESBL-carriage.  
¾ Faecal carriage in young children may represent a reservoir for intra-household 
spread of ESBL-producing K. pneumoniae. 
 
¾ The CTX-M-15-encoding gene was carried by a ~180 kb pKPN3-like IncFIIK 
plasmid, pKp848CTX, in the K. pneumoniae ST17 outbreak strain. 
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¾ Plasmid pKp848CTX encodes multiple antibiotic, heavy metal and 
thermoresistance determinants, which may have contributed to increased fitness 
and survival of the ST17 outbreak stain in the hospital environment. 
¾ Plasmid pKp848CTX seems to be well adapted to its K. pneumoniae host 
conferring negligible fitness cost and being maintained throughout intestinal 
colonization for up to two years. 
¾ Our results suggest that pKp848CTX is not capable of self-transfer when hosted 
by CTX-M-15-Kp ST17, which may have limited the extent of the NICU 
outbreak and the duration of ESBL-colonization in children and HCs.  
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7 Impact and future perspectives 
 
It is important to investigate, characterize and report outbreaks. Such 
information may be useful in the prevention and containment of future outbreaks. In 
our hospital, procedures have been changed according to our findings. Infection 
control measures, such as enhanced hand hygiene and more efficient hygienic barriers 
between patients, were implemented in the NICU during the outbreak, and have been 
maintained since. The empirical treatment for systemic infections in neonates was 
changed from the combination of ampicillin and gentamicin to penicillin and 
gentamicin, to prevent future selection of K. pneumoniae in the NICU environment. 
Furthermore, Enterobacteriaceae isolated from breast milk samples are now always 
screened for ESBL-production to prevent ESBL-transmission from mothers to infants 
via contaminated breast milk. Regular ESBL-screening of children hospitalized in the 
NICU or at admission has been discussed, but has until present not been implemented.  
Due to the increasing prevalence of ESBL-carriage in the community in most 
parts of the world, mothers may become an important source for NICU outbreaks. As 
limited data exist concerning ESBL-carriage rates in the Norwegian healthy 
population, we recently performed a study where the ESBL-carriage rate among 
pregnant women in our region, and the risk of mother-to-neonate ESBL-transmission 
has been studied (Rettedal et al., manuscript in preparation). 
In the present study, we documented that children colonized during a NICU 
outbreak are at risk for prolonged ESBL-carriage, which has implications for infection 
control measures during NICU stays and at re-admissions. Due to our results, the use 
of alert codes to identify previously colonized patients and screening at re-admission 
might be considered for 1-2 years after ESBL-colonization in the perinatal period to 
prevent ESBL-spread within NICUs or other pediatric wards. 
Plasmid stability, plasmid-host adaptation and the magnitude of plasmid-
conferred fitness costs are of importance for the persistence and spread of antibiotic 
resistance determinants. Biological costs of an antibiotic resistance plasmid and 
plasmid maintenance by the host strain during long-term colonization of a human host 
has until present not been investigated. By combining in vivo and in vitro studies, we 
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gained new insight into the dynamics between a plasmid encoding antibiotic resistance 
determinants and its host strain. Our results suggest that multidrug resistance plasmids 
may be well adapted to successful host strains, and that antibiotic resistance 
determinants may be maintained both on the plasmid and the bacterial strain level, 
without antibiotic selection, for long periods of time, also in vivo.  
Many interesting questions were raised during the plasmid study, and some of 
them remained unanswered. Therefore, we have initiated new projects, including WGS 
of the ST17 K. pneumoniae outbreak strain. By including the first and the last isolates 
from individual children, we also aim to study the microevolution of this strain and its 
plasmids on the DNA sequence level during long-term human carriage. 
The combat against AMR is a multifaceted global task. To limit further spread 
of ESBL-producing and other MDR bacteria, resistance surveillance programs, 
adequate empirical treatment recommendations, antibiotic stewardship, increased 
focus on infection control and rapid detection of antibiotic resistance are of great 
importance (335). Increased understanding of the dynamics of spread and maintenance 
of resistance determinants in hospitals, in the environment, in animals, in food and in 
the human community is needed. The interactions between plasmids encoding 
multidrug resistance and their host strains need to be further studied to better 
understand the mechanisms for the spread and maintenance of MDR bacteria also as a 
potential target for interventions.  
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9 Errata 
Page 14: The title of Paper III should be: “Persistence of a pKPN3-like CTX-M-15-
encoding IncFIIK plasmid in its Klebsiella pneumoniae ST17 host during two 
years of intestinal colonization” 
Page 63: The definition of CTX-M-15-Kp elimination should be: “Three or more 
consecutive negative faecal samples (screening interval  one month) in 
previously colonized children (The follow-up study)” 
Page 91: In the last line, the reference to a previous chapter of the discussion should be 
5.2.1. 
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Appendix 1
How to take a faecal sample 
A faecal sample is easily taken in one of the following ways. 
1. You can brush the rectal swab (a) around the anus immediately after defecation and before 
wiping.  
2. Brush the rectal swab into faeces in diapers or toilet paper.  
It is important that the rectal swab is visibly covered with faeces.  
After the test is taken, put the swab into the tube (b) which contains charcoal. Write your 
names and date of birth on the tubes. Send the rectal samples together with laboratory 
requisitions and the questionnaire to the laboratory. 
                                                                                               
  
How to fill out the laboratory requisitions 
Write your names and date of birth to the right on the top. Write the date the sample is taken. 
It is important that both samples and requisitions are well marked. 
If you need something or if you have questions, you can call Kirsti Gummedal or Beate Fet, 
tlf. 51518807/8800. 
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Appendix 2 
 
Follow-up study on newborn colonized with Klebsiella 
pneumoniae ESBL and transmission to family members  
 
 
Date of faecal sample: 
 
Project number: 
 
 
1. What is your child’s nutrition? 
  Breast feeding alone 
  Partial breastfeeding 
  Mothers milk substitution 
  Porridge or normal food is introduced 
 
2. Did your child become any milk products containing living bacteria (like Biola) for the last 
month (last three months)? 
  Yes 
  No 
 
3. Has your child been ill for the last month (last three months)? 
  Yes 
  No 
 
If yes, what kind of symptoms did your child have? 
  Fever 
  Respiratory disease or pneumonia 
  Diarrhoea or other gastrointestinal symptoms 
Other symptoms/diseases: ___________________________________________________ 
 
4. Has your child been treated with antibiotics for the last month (last three months)? 
  Yes 
  No 
If yes, please write the name of the antibiotic/s: 
______________________________________________________________ 
 
5. Has your child been admitted to a hospital for the last month (last three months)? 
  Yes 
  No 
If yes, which hospital: ______________________________________ 
 
6. Has anyone in your family been abroad for the last month (last three months)? 
  Yes 
  No 
If yes, who of you? ______________________________________________      
Which country did you visit? ________________________________ 
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7. How many family members are living in your house?  
Number of adults: 
Number and age of children:  
 
 
 
 
Thank you for your participation.  
 
Please put the questionnaire together with the faecal samples and the laboratory requisitions 
in the envelope, and send it to the laboratory. 
If you have questions, you can call Kirsti Gummedal or Beate Fet, tlf. 51518807/8800. 
  
